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Figure 1 The renin-angiotensin-aldosterone system. Angiotensin II activates angiotensin 
II type 1 and type 2 (AT1 and AT2) receptors. AT1 receptor activation in the adrenal 
results in the synthesis and release of aldosterone, which subsequently exerts ‘genomic’ 
(after hours, involving protein synthesis) or ‘non-genomic’ (within minutes, not involving 
protein synthesis) effects through either mineralocorticoid receptors (MR) or other, as 
yet unidentified, receptors. MR may occur both intracellular and on the cell membrane. 
Aldosterone upregulates both AT1 and AT2 receptors, and AT1 receptor activation also 
results in MR stimulation in an aldosterone-independent manner.  
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            
              
          
             
            
Chapter 1 
 
               
                
            
            
        
            
           
           
         
            
             
            
        
 
Adverse effects of aldosterone in the cardiovascular system 
            
            
             
            
     
Endothelial dysfunction.         
            
          
         
         
Oxidative stress, inflammation and fibrosis.        
              
          
                           Introduction and aim  
 
         
             
          
           
          
          
              
       
Arrhythmias.            
           
            
             
            
           
             
         
            
      
Interaction with angiotensin II.         
              
          
             
              
           
          
         
  
Chapter 1 
 
Aim of this thesis 
                
            
              
            
                
              
             
        
                 
                
              
              
           
  
              
            
           
             
             
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               
          
 J Biol Chem  273:  
             
      Endocrinology  138:  
                 
      Hypertension  25:  
             
           
   Endocrinology  144:  
                
            
        Circulation  
109:  
                           Introduction and aim  
 
               
        
Circulation  111:  
            
    Endocrinology  145:  
                
       
            
          Circulation 
 107:  
                
           
    Circulation  110:  
                  
      Kidney Int  57: 
 
          Kidney Int 
 67:  
               
     Hypertension  43:  
             
        
 Circ Res  71:  
             
         
  Endocrinology  135:  
             
       
     Circulation  108:  
               
          
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Introduction
It is now well-established that angiotensin (Ang) I and II
are synthesized at tissue sites. In fact, most, if not all, tissue
Ang II is synthesized locally from locally produced Ang I
[1,2], and the beneficial effects of renin-angiotensin system
(RAS) blockers are most likely due to interference with this
Ang II rather than the Ang II in circulating blood [3].
Although originally it was thought that the renin required
for such local synthesis was also locally produced, studies
in nephrectomized animals provided convincing evidence
that this is not the case [4–8]. Thus, in many tissues, in par-
ticular heart and vessel wall, local Ang I synthesis depends
on kidney-derived renin. In addition, prorenin, the inac-
tive precursor of renin, may contribute to Ang I generation
at tissue sites [9,10]. This would, however, require its local
activation following uptake from the circulation. Studies in
transgenic animals displaying (inducible) prorenin expres-
sion in the liver support this concept [11,12]. The question,
therefore, arises: Where does this circulating (pro)renin
act: extra- or intracellularly? In case of the latter, the intra-
cellular occurrence of both angiotensinogen and angio-
tensin-converting enzyme (ACE) are required to allow
intracellular Ang II generation.
Intracellular Presence of Renin
After establishing the concept that tissue renin is kidney-
derived, attention is focused on how tissues sequester
renin and/or prorenin from the circulation. Diffusion into
the interstitial space is one possibility [13,14], but evi-
dence has also been obtained for the existence of
(pro)renin receptors [15••,16–18]. Two such receptors
have now been identified: the mannose 6-phosphate/insu-
lin-like growth factor II (M6P/IGFII) receptor [9,16] and a
recently cloned “renin receptor” [15••], which is identical
to the vacuolar adenosine triphosphate (ATP) synthase
membrane sector-associated protein M8-9 [19]. Both
receptors bind renin and prorenin equally well. M6P/IGFII
receptors internalize M6P-containing renin and prorenin,
and prorenin internalization is followed by intracellular
activation (through proteolytic cleavage of the proseg-
ment) of prorenin to renin. Such activation, however, did
not result in intracellular angiotensin generation in cardiac
and vascular cells, mainly because these cells did not con-
tain or sequester angiotensinogen [9,20••]. Therefore, this
receptor may actually be a clearance receptor for
(pro)renin.
Binding to the “renin receptor” facilitates Ang I genera-
tion on the cell surface, not only following binding of
renin, but also following binding of prorenin. The latter
suggests that prorenin, once bound to this receptor, under-
goes a conformational change (uncovering the active site)
or is proteolytically activated to renin.
Finally, a third, as yet unidentified, (pro)renin receptor
has been proposed, based on observations that rat cardi-
omyocytes internalize prorenin (but not renin) in an M6P/
IGFII-independent manner [18]. Interestingly, internaliza-
tion of mouse ren-2d, but not rat, prorenin via this uniden-
tified mechanism resulted in angiotensin generation. The
authors attributed this difference to the fact that mouse
ren-2d prorenin is unglycosylated, because glycosylation
will determine the pathway of internalization and/or the
degree of intracellular activation. However, care must be
taken when interpreting these results, because the intracel-
lular Ang I and II levels that were detected by direct radio-
immunoassay after adding mouse ren-2d prorenin were 100
to 200 pg/mg protein—ie, approximately three to four
orders of magnitude higher than the in vivo levels of Ang I
and II in the heart (5–20 pg/g tissue) [4–6]. Such high lev-
els seem unlikely in view of the low angiotensinogen levels
in the rat heart [8,21], and future studies should, therefore,
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re-evaluate these high levels, preferably using high-perfor-
mance liquid chromatography separation prior to the
radioimmunoassay. Such studies should simultaneously
address the intracellular occurrence of angiotensinogen
and ACE.
In summary, in cells that do not synthesize (pro)renin,
binding and internalization of both renin and prorenin
results in the accumulation of these RAS components in
intracellular compartments. The consequences of this
uptake are not yet entirely clear, and one possibility is that
it reflects clearance.
Cells that do synthesize (pro)renin (eg, renal juxta-
glomerular cells and adrenal glomerulosa cells) secrete
renin from storage granules, and release prorenin constitu-
tively. In addition, renin-synthesizing cells in adrenal,
brain, and heart (but not kidney) express an alternative
renin transcript, called exon 1A renin [22,23]. This tran-
script codes for a truncated prorenin, which is not targeted
to the secretory pathway, but remains intracellular. Its func-
tion is currently unknown. In the adrenal, it is transported
to mitochondria [22]. Although its messenger RNA levels
are elevated in the heart after myocardial infarction [23],
the actual protein has not yet been demonstrated in cardiac
tissue. The lack of renin-mediated Ang I–generating activity
in cardiac tissue following a bilateral nephrectomy [4,8], as
well as the fact that the Ang I–generating activity in hearts
of nephrectomized animals does not increase following
procedures that activate prorenin [4,8], suggest that trun-
cated prorenin, if present in the heart, is not involved in
angiotensin generation. The strong relationship between
plasma and cardiac Ang I–generating activity under normal
and pathologic conditions [21,24] also argues against the
idea that locally synthesized truncated prorenin contrib-
utes to cardiac Ang I generation.
Intracellular Presence of Angiotensinogen, 
Angiotensin-converting Enzyme, and 
Angiotensin Receptors
Data on the intracellular presence of angiotensinogen and
ACE are scarce. Angiotensinogen-synthesizing cells nor-
mally secrete angiotensinogen into the extracellular space,
without storing it intracellularly. The tissue levels of angio-
tensinogen in non–angiotensinogen-synthesizing tissues
are compatible with the idea that the presence of angio-
tensinogen is limited to the extracellular fluid—ie, blood
and interstitial fluid [4,8,21,24]. Intracellular accumula-
tion will only occur under (artificial) conditions where the
N-terminal sequence required for secretion is deleted [25].
Evidence for angiotensinogen internalization could not be
obtained [9,26], and, thus, the intracellular presence of
angiotensinogen observed by some authors is most likely
related to its intracellular synthesis and subsequent secre-
tion [27,28].
Intracellular dialysis of Ang I into hamster cardiomyo-
cytes resulted in Ang II–induced effects on cell coupling, as
evidenced by the suppression of these effects following
simultaneous intracellular application of enalaprilat [29].
Although this finding is in agreement with the concept that
ACE is present intracellularly, Beldent et al. [30] were
unable to demonstrate ACE activity in the cytosol. Possi-
bly, therefore, Ang II was generated on the cell surface fol-
lowing the release of intracellularly applied Ang I to the
extracellular space. Alternatively, as enalapril also increased
cell coupling in the absence of Ang I, its effects may have
been nonspecific (ie, unrelated to Ang II). The modest
effects of losartan compared with enalapril in the same
experimental setup (increases in junctional conductance of
16% and 72%, respectively) support this latter possibility.
A second possibility is that losartan has blocked endoge-
nous intracellular Ang II [31]. Even if this is true, it cannot
be concluded that this Ang II originated from an extracellu-
lar source prior to the removal of the myocytes from the
hamster [31]. The blocking effects of losartan, both at base-
line and after the addition of Ang II [32], are in full agree-
ment with the idea that Ang II type 1 (AT1) receptors occur
intracellularly [33•,34,35], particularly because the effects
of losartan were observed only after intracellular applica-
tion and not after extracellular application of the AT1
receptor antagonist [32].
Intracellular Presence of Angiotensin I and 
Angiotensin II
Studies in which the blood plasma, interstitial, and tissue
levels of Ang I, as well as its subcellular distribution, were
determined revealed that tissue Ang I is restricted to the
extracellular fluid compartment [36,37]. Thus, intracellular
Ang I generation seems unlikely. In contrast, numerous
reports support the intracellular presence of Ang II in mul-
tiple organs, including brain, heart, adrenal, and kidney
[37–41]. In fact, most, if not all, tissue Ang II appears to be
cell-associated [36,37], and most of this angiotensin is of
local origin. Because its subcellular distribution is indistin-
guishable from that of systemically infused 125I-labeled
Ang II (which is exclusively of extracellular origin) [37],
the most likely source of this cell-associated Ang II is the
extracellular compartment. AT1-receptor antagonists
greatly reduce the tissue accumulation of infused Ang II,
thereby suggesting that AT1 receptor-dependent endocyto-
sis underlies this uptake [36,37,39,40]. Extracellular Ang II
is rapidly degraded by angiotensinases (t½ < 1 minute)
[36], whereas receptor-bound Ang II has a half life > 10
minutes [39]. Thus, under conditions in which complete
AT1-receptor blockade is achieved, tissue Ang II levels
should decrease. The data of Mazzolai et al. [42••] fully
support this concept. Furthermore, tissues with the highest
AT1 receptor density display the highest Ang II levels [39].
Taken together, therefore, the currently available in vivo
data strongly suggest that generation of Ang I and II occurs
extracellularly. The most likely site for tissue angiotensin
generation, in view of the fact that both ACE and renin
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receptors occur on the cell membrane, is the cell surface.
Cell-surface generation is supported by studies revealing
that membrane-bound renin cleaves angiotensinogen
much more efficiently than soluble renin [15••] and that
Ang II-mediated effects occur at 100-fold lower extracellu-
lar Ang II levels during prorenin + angiotensinogen appli-
cation than during Ang II application [20••]. Apparently,
angiotensin generation on the cell surface results in high
Ang II levels in the micro-environment of AT receptors,
allowing immediate binding of Ang II to its receptors
rather than “loss” of Ang II into the extracellular space.
Such efficient Ang II generation will not occur when non–
membrane-bound enzymes, such as chymase, are involved
[43], and this may explain why such enzymes do not con-
tribute to Ang II synthesis in vivo.
In vitro data showing that cultured cells (mainly cardi-
omyocytes) release Ang II, particularly after stretch [44],
appear to contradict the conclusion discussed earlier. How-
ever, the Ang II levels measured in these experiments were
up to 1000-fold higher than the in vivo levels [45] and
could not always be confirmed by others [26,46•]. An
argument for stretch-induced Ang II release, even when
such release could not be demonstrated, has always been
that AT1 receptor antagonists block the stretch-induced
hypertrophic response. Recently, however, Zou et al. [46•]
demonstrated that mechanical stress activates AT1 recep-
tors without the involvement of Ang II. Most likely, there-
fore, Ang II release from intracellular sources in cell culture
studies is a methodologic artefact.
Is Angiotensin II An Intracrine Hormone?
The mere fact that Ang II, when applied [32,35] or
expressed [33•,34] intracellularly, exerts effects is, of
course, by no means evidence for its intracellular synthesis.
Similarly, the intracellular presence of Ang II does not
prove that Ang II is synthesized in the cell, because, as dis-
cussed earlier, it may simply reflect AT1 receptor-mediated
internalization. In fact, signaling is believed to depend, at
least in part, on internalization [47], and thus, it is not sur-
prising that Ang II, when applied or expressed intracellu-
larly, exerts effects: it will stimulate internalized receptors.
Internalization is also required to explain the recently
reported interaction between Ang II and aldosterone
[48,49], assuming that this involves intracellular mineralo-
corticoid receptors. Ré [50] defined an “intracrine” hor-
mone not only as a hormone that is synthesized and acts
intracellularly, but also as a hormone that is synthesized or
secreted by a cell and then taken up by that same cell to act
in the intracellular space. Therefore, even Ang II which,
after its extracellular synthesis on the cell surface, is inter-
nalized and acts intracellularly, can be considered to be an
intracrine hormone.
Conclusions
Although renin, Ang II, and AT1 receptors can be demon-
strated intracellularly, evidence for the intracellular presence
of angiotensinogen, Ang I, and ACE is lacking. Rather, the
tissue levels of both Ang I and angiotensinogen, when com-
pared with their levels in blood and interstitial fluid, do not
allow the conclusion that these components are cell-associ-
ated. Furthermore, the subcellular distribution of endoge-
nous Ang II is indistinguishable from that of exogenously
applied 125I-Ang II. Consequently, Ang II synthesis must
occur extracellularly, for instance on the cell surface, where
both renin receptors and ACE are located. Subsequent inter-
nalization of Ang II via AT1 receptors is not only a prerequi-
site for Ang II to induce a full response, but could also
explain why both Ang II and AT1 receptors can be found
intracellularly. The latter probably also underlies ex vivo cell
culture studies showing effects of intracellularly applied Ang
II and/or AT1 receptor antagonists. Finally, the intracellular
presence of renin in cardiac and vascular cells most likely
represents a clearance phenomenon, whereas the function
of intracellular truncated (exon 1A) prorenin in adrenal
mitochondria remains to be determined.
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Adrenal
Adrenal Angiotensin: Origin and Site of
Generation
Jorge P. van Kats, Wenxia Chai, Dirk J. Duncker,
Maarten A.D.H. Schalekamp, and A.H. Jan Danser
Background: Circulating angiotensin (Ang) II accumu-
lates in adrenal tissue via binding to Ang II type 1 (AT1)
receptors, reaching levels that are 15 to 20 times higher than
in blood. Adrenal tissue contains a second renin transcript
that gives rise to a truncated prorenin representing a cytosolic
form of renin. Here we investigated what percentage of
adrenal Ang II originates at adrenal tissue sites, and whether
intracellular renin contributes to adrenal angiotensin produc-
tion.
Methods: Concentrations of endogenous and iodine-
125 (125I)–labeled Ang I and II were measured in adrenal
tissue and blood from pigs after 125I-Ang I infusion.
Results: In the adrenal tissue in all animals, 125I-Ang I
was undetectable. In untreated pigs, adrenal 125I-Ang II
was 17� 1 times arterial 125I-Ang II, and tissue Ang I and
II were 5� 1 and 388� 40 times higher than plasma Ang
I and II. The AT1 receptor antagonist eprosartan reduced
adrenal 125I-Ang II accumulation by 80%, and increased
plasma Ang II to a greater degree than tissue Ang II. As a
consequence, eprosartan equally reduced the tissue/plasma
concentration ratios of both Ang II and 125I-Ang II. Cap-
topril did not alter 125I-Ang II accumulation, and acutely,
but not chronically, reduced the adrenal Ang II/I ratio.
Conclusions: More than 90% of adrenal Ang II orig-
inates at adrenal tissue sites. Local adrenal Ang II gener-
ation occurs extracellularly and is followed by internalization
via AT1 receptor-mediated endocytosis. Enhanced angio-
tensin generation, combined with incomplete AT1 receptor
blockade and the large adrenal AT1 receptor reserve, ex-
plains why eprosartan increased rather than decreased
adrenal Ang II. Our data do not support angiotensin gen-
eration by truncated prorenin. Am J Hypertens 2005;18:
1104–1110 © 2005 American Journal of Hypertension,
Ltd.
Key Words: Adrenal, angiotensin, intracellular, recep-
tor, renin.
A drenal tissue contains high levels of angiotensin(Ang) II,1 and it is generally believed that thisAng II originates from local production within
adrenal tissue. All components required to generate Ang II
locally are present in the adrenal2–5 and in particular renin
does not disappear from adrenal tissue after a bilateral
nephrectomy.3,5,6 This finding, which contrasts with the
complete disappearance of renin from cardiac and vascular
tissue after nephrectomy,7,8 supports the concept of kid-
ney-independent renin (and Ang II) synthesis in the adre-
nal gland. Moreover, adrenal renin levels, unlike plasma
renin levels, correlate well with aldosterone production,9,10
thereby confirming the concept that locally synthesized (in
addition to circulating) Ang II affects adrenal aldosterone
synthesis.
Although renin is considered to be a secretory protein
(generating Ang I extracellularly), recent studies suggest
that adrenal tissue contains a second renin transcript that
gives rise to a truncated prorenin representing a cytosolic
form of renin.4 This truncated prorenin is transported into
adrenal mitochondria, where it may contribute to aldoste-
rone biosynthesis.4 Other mechanisms resulting in the
intracellular presence of renin include the internalization
of renin or prorenin or both via either unidentified or
mannose 6-phosphate/insulin-like growth factor II recep-
tors,11–13 and the subsequent intracellular activation of
prorenin to renin.
Urata et al,2 in a subcellular fractionation study, were
unable to co-localize renin, angiotensinogen, and angio-
tensin-converting enzyme (ACE) in adrenal cells, and thus
proposed that adrenal angiotensin production occurs by
extracellular means. However, their study did not include
the high-density fractions containing mitochondrial trun-
cated prorenin. Subcellular fractionation also demon-
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strated that �95% of adrenal Ang II is cell associated.14
Although this could suggest that intracellular Ang II syn-
thesis does occur, it might also be explained on the basis
on internalization of extracellularly generated Ang II. In
support of the latter, circulating Ang II accumulates in
adrenal tissue through Ang II type 1 (AT1) receptor-
mediated endocytosis, reaching steady-state levels in ad-
renal tissue that are 15 to 20 times higher than its levels in
arterial plasma.15 Accumulation of Ang II was also ob-
served in kidney and heart, although at a much lower
level.15,16 Thus, the question arises what percentage of
adrenal Ang II actually originates at adrenal tissue sites,
and what percentage is taken up from blood.
It was the aim of the present study to determine the
origin of adrenal Ang II. In addition, we investigated the
possibility of intracellular Ang II production in the adrenal
by truncated prorenin. All questions were addressed in a
study in pigs by measuring the adrenal and plasma levels
of iodine-125 ( 125I)–labeled and endogenous Ang I and II
during systemic 125I-Ang I infusions. Because 125I-labeled
and endogenous angiotensins are pharmacokinetically in-
distinguishable,17 a comparison of the levels of radiolabeled
and endogenous angiotensins under various conditions
will not only provide detailed information about the con-
tribution of circulating Ang I and II to the adrenal angio-
tensin content but also, in view of the fact that adrenal
125I-Ang II is by definition of extracellular origin, will
shed light on the site of adrenal angiotensin generation.
Methods
Animals
All experiments were carried out under the regulations of the
Animal Care Committee of the Erasmus Medical Center,
Rotterdam, The Netherlands, in accordance with the
“Guide for the Care and Use of Laboratory Animals” as
published by the United States National Institutes of
Health. A total of 45 Yorkshire � Landrace pigs (age 2 to
3 months, weight 25 to 30 kg) of either sex were included
in the study. Five animals were untreated, and four pigs
were treated with captopril (25 mg twice daily) for 3 days.
In the 36 remaining animals a suture was placed around
the left circumflex coronary artery to examine the effect of
coronary ligation on the cardiac levels of Ang II in these
animals.18 The left circumflex coronary artery was perma-
nently ligated in 24 animals, whereas the suture was re-
moved in 12 animals (sham operation). Of the
permanently ligated animals, six received captopril (25 mg
orally, twice daily), and five animals received the AT1
receptor antagonist eprosartan (400 mg orally, twice daily;
a kind gift of Dr. P.K. Weck, SmithKline Beecham, Col-
legeville, PA). This dose of eprosartan blocks Ang II–
induced pressor responses by �95%.18 Treatment was
started 12 to 24 h after ligation and was continued for 3
weeks. Coronary ligation did not alter the adrenal or
plasma angiotensin levels (data not shown), and the data of
all untreated pigs were therefore combined into one con-
trol group.
Instrumentation and 125I-Ang I Infusion
The 125I-Ang I infusions were given to all animals. In the
untreated animals that received a suture around the left
circumflex coronary artery, the infusions were given 1, 3,
or 6 weeks after (sham) coronary ligation, and in the treated
animals the infusions were given at the end of the treat-
ment period, within 3 h after the last dose. Animals were
prepared for administration of anesthetic and 125I-Ang I,
and for blood and tissue sampling as previously de-
scribed.15,18 After a stabilization period of 30 to 45 min
after completion of instrumentation, animals were subjected
to a 1-h infusion of 125I-Ang I (�1 to 5� 106 cpm/min) into
the left ventricle. Both 125I-Ang I and 125I-Ang II reach
steady-state levels in plasma within 10 min, and in adrenal
tissue within 60 min, without affecting blood pressure.15
Collection of Blood and Tissue Samples
To measure the plasma levels of 125I-labeled and endog-
enous Ang I and II, blood samples (5 to 10 mL) were taken
from the aorta during the infusion of 125I-Ang I as de-
scribed before.15 Plasma was stored at�70°C and assayed
within 3 days.
Adrenal tissue was collected as follows. The heart was
stopped by fibrillation while the 125I-Ang I infusion was
still running. The abdomen was opened by a longitudinal
incision, and both adrenal glands were rapidly dissected.
The adrenal glands were immediately frozen in liquid nitro-
gen and stored at �70°C.
Measurement of Angiotensins
The 125I-labeled and endogenous Ang I and Ang II were
measured as previously described,7,15 using SepPak ex-
traction and high-performance liquid chromatography
(HPLC) separation. The concentrations of 125I-labeled and
endogenous angiotensins were not corrected for losses
occurring during extraction and separation (approximately
20% to 30% in whole tissue homogenates and �10% in
plasma15). For Ang I, the lower limit of detection was
0.5 fmol/mL of plasma and 1 fmol/g of tissue. For Ang II,
the lower limit of detection was 0.3 fmol/mL of plasma
and 0.5 fmol/g of tissue.
Calculations
In a previous study15 we observed that the adrenal tissue/
arterial plasma concentration ratio of 125I-Ang II during
125I-Ang I infusion was equal to that during 125I-Ang II
infusion. Thus the 125I-Ang II that was present in adrenal
tissue was derived from arterially delivered 125I-Ang II
and not, via conversion, from arterially delivered 125I-Ang
I. The adrenal tissue level of Ang II (fmol/g) that origi-
nates from angiotensin in the circulation was therefore
calculated as follows:
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[Ang IItissue] originating from circulation
�R� [Ang IIart], (1)
in which [Ang IIart] is the steady-state concentration of
Ang II in arterial plasma (fmol/mL), and R is defined by
the equation:
R� [125I-AngIItissue] ⁄ [125I-AngIIart], (2)
in which [125I-Ang IItissue] and [
125I-Ang IIplasma] are the
steady-state concentrations of 125I-Ang II in tissue (cpm/g)
and arterial plasma (cpm/mL), respectively.
Data Analysis
Data are expressed as mean � SEM. Statistical analysis
was by unpaired t test or one-way analysis of variance,
followed by post hoc evaluation according to Tukey or
Dunnet where appropriate. Statistical significance was ac-
cepted at P � .05.
Results
Untreated Pigs
Figures 1 and 2 show the plasma and tissue Ang I and II
levels in untreated pigs (n � 30). Tissue Ang I was �5
times higher than plasma Ang I, and tissue Ang II was
�400 times higher than plasma Ang II (Table 1). The
125I-Ang I was not detectable in adrenal tissue (Fig. 3),
whereas adrenal 125I-Ang II was 17.4 � 1.1 times higher
than arterial plasma 125I-Ang II (Table 1). From these data
it can be calculated that all adrenal Ang I, and �90% of
adrenal Ang II, originates from local production in the
adrenal (Fig. 2). By far, 125I-Ang II was the most impor-
tant 125I-labeled angiotensin metabolite in the adrenal
(Fig. 3).
Effect of RAS Blockade
Acute captopril treatment (n � 4) lowered the Ang II
levels in arterial plasma (P � .05) (Fig. 1). It tended to
increase adrenal Ang I and to decrease adrenal Ang II
(Fig. 2), but the differences were not significant. However,
the Ang II/I ratio in adrenal tissue, a measure of ACE
activity, did decrease by �65% (P � .05) (Fig. 4). Acute
captopril treatment also significantly reduced the Ang II/I
and 125I-Ang II/I ratios in plasma (P� .01 for both) (Fig. 4).
During acute captopril treatment, adrenal 125I-Ang I re-
mained undetectable, and the tissue/blood plasma concen-
tration ratio of 125I-Ang II was identical to that in
untreated pigs. The tissue/blood plasma concentration ra-
tio of Ang II rose twofold (P � .01) (Table 1), and the
contribution of circulating Ang II to the adrenal Ang II
tissue levels decreased from 44 � 10 to 15 � 4 fmol/g
(P � .05) (Fig. 2). Acute captopril treatment did not alter
the amount of Ang II synthesized at adrenal tissue sites.
After chronic captopril treatment (n � 6), arterial
plasma Ang I rose five- to tenfold (P � .05) (Fig. 1), and
arterial plasma Ang II returned to control values. Adrenal
angiotensin levels equaled those in untreated pigs (Fig. 2).
The arterial plasma 125I-Ang II/I and Ang II/I ratios re-
mained reduced (Fig. 4), but the adrenal tissue Ang II/I
ratio returned to control values. Chronic captopril treat-
ment did not affect the adrenal uptake of arterial 125I-Ang
I and II (Table 1), and the contribution of circulating Ang
II to adrenal Ang II (85 � 30 fmol/g) was not different
from that in untreated pigs. The amount of Ang I and II
synthesized at adrenal tissue sites was also identical to that
in untreated pigs (Fig. 2).
Chronic eprosartan treatment (n � 5) induced similar
(fourfold) increases in plasma and adrenal Ang I (P� .05)
(Figs. 1 and 2). It increased plasma Ang II to a larger
degree than tissue Ang II (sixfold v threefold), and, as a
consequence, the adrenal tissue/arterial plasma concentra-
tion ratio of Ang II was reduced by 70% (P � .02).
Eprosartan did not significantly affect the 125I-Ang II/I
ratio in plasma (Fig. 4). It did reduce the adrenal uptake of
FIG. 1. Plasma levels of angiotensin (Ang) I and II in pigs that were
untreated (control; n � 30), treated with captopril for 3 days (acute
captopril; n � 4) or 3 weeks (chronic captopril; n � 6), or treated
with eprosartan for 3 weeks (chronic eprosartan; n � 5). Data are
mean � SEM. *P � .05 v control.
FIG. 2. Adrenal levels and origin of angiotensin (Ang) I and II in
pigs that were untreated (control; n� 30), treated with captopril for
3 days (acute captopril; n� 4) or 3 weeks (chronic captopril; n� 6),
or treated with eprosartan for 3 weeks (chronic eprosartan; n � 5).
Adrenal Ang I did not originate in plasma. Data are mean � SEM.
*P � .05 v control.
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125I-Ang II by 79% (P � .01) (Table 1). The 125I-Ang I
remained undetectable in adrenal tissue in eprosartan-
treated pigs. Eprosartan did not alter the contribution of
circulating Ang II to the adrenal Ang II tissue levels (70�
25 fmol/g), and it greatly increased the synthesis of Ang I
and II at adrenal tissues sites (P � .05) (Fig. 2).
Discussion
The present study shows that accumulation of circulating
Ang II in the adrenal gland accounts for approximately 15
to 85 fmol Ang II/g wet weight. Such levels are compa-
rable to or higher than the total amount of Ang II (per
gram wet weight) in heart and kidney.1,19,20 Yet, the total
adrenal Ang II levels are �10 times higher, both with and
without RAS blockade; thus, despite the considerable con-
tribution of circulating angiotensins (supporting a role for
circulating Ang II in the adrenal), the majority (�90%) of
adrenal Ang I and II is derived from local origin, ie, it is
synthesized at adrenal tissue sites, independently of either
circulating Ang I or II.
Where does angiotensin generation at adrenal tissue
sites occur? Intracellular Ang II synthesis is favored by
previous studies showing that adrenal tissue contains a
cytosolic form of renin (truncated prorenin)4 and that
�95% of adrenal Ang II is cell associated.14 The current
observation that adrenal Ang II levels increase during AT1
receptor blockade also appears to support this concept.
However, to put these findings into perspective, and as
indicated in Fig. 5, the following points should be taken
into consideration: 1) 125I-Ang II accumulates at tissue
sites through AT1 receptor-mediated endocytosis,
15 2)
�95% of tissue 125I-Ang II is cell-associated (ie, is either
membrane-bound or intracellular)14; and 3) treatment with
eprosartan increases circulating (extracellular) Ang II but
not 125I-Ang II. It is thus not surprising that eprosartan
greatly reduces the 125I-Ang II tissue/plasma concentration
ratio. If adrenal Ang II, like 125I-Ang II, is of extracellular
origin, eprosartan should reduce the Ang II tissue/plasma
concentration ratio to the same degree as that of 125I-Ang
II. In contrast, if adrenal Ang II is generated intracellu-
larly, the Ang II tissue/plasma concentration ratio change
after eprosartan should not parallel that of 125I-Ang II. It
may not change at all (Fig. 5), or it might even increase.
Our data, showing an identical eprosartan-induced reduc-
tion in the tissue/plasma concentration ratio of Ang II and
125I-Ang II (by 70% and 79%, respectively), strongly
favor the first possibility. Thus Ang II synthesis at adrenal
tissue sites occurs extracellularly, either in the interstitial
fluid or on the cell surface.
Extracellular Ang II generation implies that tissue Ang
I is restricted to the extracellular fluid compartment, ie, the
interstitial fluid. The latter accounts for �10% of adrenal
tissue weight, and thus it can be estimated that the adrenal
interstitial Ang I levels in untreated animals are �200 fmol/
mL, or 50 times its levels in circulating blood. The adrenal
interstitial Ang II levels would be �300 fmol/mL, pro-
vided that all of the 5% of adrenal Ang II that was
previously found in the cytosolic/extracellular fluid frac-
tion (after subcellular fractionation14) is present in inter-
stitial fluid. Interestingly, these interstitial levels resemble
the Ang I and II levels that were recently detected in the
medium of cultured human adrenocortical NCI-H295
cells.21
Acute ACE inhibition with captopril lowered the adre-
nal Ang II/I ratio by approximately 65%. This reduction is
less complete than the 80% to 90% decrease in the ratio of
circulating Ang II and I, and it most likely reflects the
inability of captopril, at the dose applied in this study, to
fully block adrenal ACE. It does confirm, however, that
orally applied captopril reaches adrenal tissue sites. Remark-
ably, during prolonged captopril treatment, the ratio of cir-
culating Ang II and I remained reduced, whereas the adrenal
Ang II/I ratio returned to normal levels. Similar observations
were made previously in heart and kidney18–20; and collec-
tively these data suggest that, chronically, ACE inhibition
is overcome at tissue sites, either because of ACE upregu-
lation in tissues or because other converting enzymes
come into play.1,22,23
Chronic AT1 receptor blockade increased both the cir-
culating and adrenal angiotensin levels. In accordance
with a previous study,24 the increase in circulating Ang II
was two to three times as large as the increase in adrenal
Table 1. Adrenal tissue/arterial blood plasma concentration ratios of endogenous and radiolabeled angio-
tensin (Ang) I and II
Peptide
No Treatment
(n � 30)
Acute Captopril
Treatment
(n � 4)
Chronic Captopril
Treatment
(n � 6)
Chronic Eprosartan
Treatment
(n � 5)
Ang I 5.1 � 0.6 5.6 � 1.5 1.5 � 0.5 4.0 � 2.4
Ang II 388 � 40 757 � 157* 397 � 138 120 � 20¶
125I-Ang I 0 0 0 0
125I-Ang II 17.4 � 1.1 20.1 � 4.5 20.7 � 4.4 3.7 � 0.8*
Data are mean � SEM. Steady-state plasma 125I-Ang I and II levels were 471 � 22 and 302 � 27 cpm/mL, 2906 � 935 and 539 � 289
cpm/mL, 620 � 69 and 101 � 17 cpm/mL, and 563 � 82 and 385 � 16 cpm/mL in the control, acute captopril, chronic captopril, and chronic
eprosartan groups, respectively.
* P � .01; ¶ P � .02 v untreated.
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Ang II. The eprosartan-induced increases in plasma and
adrenal Ang I were similar. Thus, for a given eprosartan-
induced rise of Ang I, the rise in Ang II at adrenal tissue
sites was smaller than in the circulation. Campbell et al have
demonstrated that this is not due to a decrease in adrenal
ACE.24 Taking into account that AT1 receptor binding
protects Ang II against rapid metabolism,15,25 a more
likely explanation of this observation is that AT1 receptor
blockade has prevented locally generated Ang II from
binding to AT1 receptors, thereby decreasing its half life.
Adrenal AT1 receptor density ranges from 20 to
100 pmol/g.26,27 Thus, at the adrenal Ang II levels mea-
sured in untreated pigs in the present study (�0.5 pmol/g),
�97.5% of adrenal AT1 receptors is free. Eprosartan
blocked approximately 80% of the adrenal AT1 receptors
(evidenced by the 79% reduction in adrenal 125I-Ang II
uptake). The remaining 20% would easily allow the three-
fold increase in the adrenal Ang II levels observed after
eprosartan, and only under conditions where complete or
near complete (�97.5%) AT1 receptor-blockade is ob-
tained a decrease in tissue Ang II levels will occur.28
How do AT1 receptor blockers exert effects, if they
increase rather than decrease the amount of AT1 receptor–
internalized Ang II per gram of tissue? To induce an effect,
Ang II needs to stimulate a threshold number of AT1
receptors per cell. Local Ang II generation (eg, on the cell
surface) typically allows such a high degree of regional
AT1 receptor stimulation. During eprosartan treatment,
this is no longer possible, although (due to the increased
extracellular Ang II generation and the incomplete AT1
receptor blockade), Ang II may still bind to AT1 receptors
without, however, reaching the threshold stimulation level
in an individual cell. In other words, a high degree of
regional AT1 receptor stimulation is replaced by a low
degree of overall AT1 receptor stimulation. Although this
FIG. 3. High-performance liquid chromatography elution profile of
iodine-125 (125I)–labeled angiotensins (Ang) in adrenal tissue mea-
sured by gamma counting. Samples were obtained from a control
pig (top panel), a captopril-treated pig (middle panel), and an
eprosartan-treated pig (bottom panel), after a 1-h infusion of
125I-Ang I. Retention times of radiolabeled standards: (a) 125I-
tyrosine; (b) 125I-Ang–(4–8); (c) 125I-Ang II; (d) 125I-Ang I.
FIG. 4. Ratio of endogenous and radiolabeled angiotensin (Ang) II
and I in plasma (top panel) and adrenal tissue (bottom panel) in
pigs that were either untreated (control; n � 30), treated with
captopril for 3 days (acute captopril; n � 4) or 3 weeks (chronic
captopril; n � 6), or treated with eprosartan for 3 weeks (chronic
eprosartan; n � 5). The 125I-Ang I was undetectable in adrenal
tissue, so the tissue 125I-Ang II/I ratio could not be calculated. Data
are mean � SEM. *P � .01, #P � .05 v control.
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will reduce the AT1 receptor–mediated effects of Ang II, it
does not necessarily lower the tissue levels of Ang II.
A similar mechanism may underlie the beneficial ef-
fects of ACE inhibition, which also appear to occur in the
absence of a change in tissue Ang II content.18,19 Nor-
mally, ACE generates Ang II in a highly efficient manner,
in close proximity of AT1 receptors.
22,29,30 Consequently,
little Ang II needs to be generated to obtain maximal
(regional) AT1 receptor stimulation. During chronic ACE
inhibition, the increase in Ang I generation will still allow
Ang II generation, either by noninhibited ACE or by
non–ACE such as chymase.22,31 However, this type of
Ang II generation is less efficient, because it does not
result in a high level of regional AT1 receptor stimulation.
In particular, Ang II generated by chymase (which is
localized in the adventitia32) will be subject to rapid me-
tabolism in the interstitial space on its way to AT1 recep-
tors25,33 and thus is less likely to result in a high regional
AT1 receptor occupancy. Again, a low overall AT1 recep-
tor occupancy will occur, below the minimum per cell
required to induce an effect.
In conclusion, adrenal Ang II originates both in the
circulation and at adrenal tissue sites. Local adrenal Ang II
generation occurs extracellularly and is followed by inter-
nalization via AT1 receptor–mediated endocytosis. The
large adrenal AT1 receptor density allows adrenal Ang II
levels to increase further during eprosartan treatment, even
when near-complete AT1 receptor blockade is obtained.
The absence of intracellular Ang II generation at adrenal
tissue sites suggests that intracellular mitochondrial renin3
may exert other, as yet unidentified, effects.
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Genomic and nongenomic effects of aldosterone in the rat heart:
why is spironolactone cardioprotective?
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3Jos M.J. Lamers & *,1A.H. Jan Danser
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1 Mineralocorticoid receptor (MR) antagonism with spironolactone reduces mortality in heart
failure on top of ACE inhibition. To investigate the underlying mechanism, we compared the actions
of both aldosterone and spironolactone to those of angiotensin (Ang) II in the rat heart.
2 Hearts of male Wistar rats were perfused according to Langendorff. Ang II and aldosterone
increased left ventricular pressure (LVP) by maximally 1174 and 972%, and decreased coronary
flow (CF) by maximally 3677 and 2074%, respectively. Spironolactone did not significantly affect
LVP or CF.
3 In hearts that were exposed to a 45-min coronary artery occlusion and 3 h of reperfusion, a 15-min
exposure to spironolactone prior to occlusion reduced infarct size (% of risk area) from 6872 to
4573%, similar to the reduction (3472%) observed following ‘preconditioning’ (15min occlusion
followed by 10min reperfusion) prior to the 45-min occlusion. Aldosterone exposure did not affect
infarct size (7175%).
4 In cardiomyocytes, aldosterone decreased [3H]thymidine incorporation maximally by 7373%,
whereas in cardiac fibroblasts it decreased [3H]proline incorporation by 3377%. Spironolactone
inhibited both effects. Ang II increased DNA and collagen synthesis, and these effects were reversed
by aldosterone.
5 In conclusion, aldosterone induces positive inotropic and vasoconstrictor effects in a nongenomic
manner, and these effects are comparable to those of Ang II. Aldosterone reduces DNA and collagen
synthesis via MR activation, and counteracts the Ang II-induced increases in these parameters. MR
blockade reduces infarct size and increases LVP recovery following coronary artery occlusion. The
MR-related phenomena may underlie, at least in part, the beneficial actions of spironolactone in heart
failure.
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Introduction
Plasma aldosterone levels are elevated in patients with
congestive heart failure, even when long-term ACE inhibitor
therapy results in complete inhibition of membrane-bound
ACE (Jorde et al., 2002). This elevation is not due to
angiotensin (Ang) II generation by non-ACE enzymes such
as chymase (MaassenVanDenBrink et al., 1999; Jorde et al.,
2002; Tom et al., 2003), and thus factors other than Ang II
(e.g., potassium, corticotropin and catecholamines) are re-
sponsible for the increased aldosterone production in heart
failure during ACE inhibition (Weber, 2001).
Aldosterone excess has deleterious effects on cardiac func-
tion (Delcayre & Silvestre, 1999; Beggah et al., 2002; Sun et al.,
2002; Ahokas et al., 2005), and treatment of patients
experiencing severe heart failure with the aldosterone receptor
antagonist spironolactone improves the morbidity and mortal-
ity on top of ACE inhibition (Pitt et al., 1999). The underlying
mechanism of this beneficial effect is not entirely clear. Since
the aldosterone receptor (mineralocorticoid receptor (MR))
occurs both in the kidney and extrarenal tissues like the heart
and the vessel wall (Lombe`s et al., 1995; Mazak et al., 2004;
Oberleithner et al., 2004), it is believed that spironolactone may
exert its effects, at least in part, independently of the kidney. It
has even been suggested that aldosterone, like Ang II (Danser
et al., 1994; van Kats et al., 1998), is synthesized locally in the
heart (Silvestre et al., 1998; 1999).
The MR-mediated effects of aldosterone are referred to as
genomic effects. These effects involve binding of aldosterone to
the intracellular MR (KdE1–2 nM) and the translocation of
the steroid–MR complex to the nucleus, where it acts as a
transcriptional regulator, inducing effects after several hours.
In addition, rapid ‘nongenomic’ effects of aldosterone*Author for correspondence; E-mail: a.danser@erasmusmc.nl
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(occurring within minutes) have been described (Lo¨sel et al.,
2002). These effects are likely to be transmitted via specific
membrane receptors. They occur at subnanomolar levels of
aldosterone, and involve, among others, inositol 1,4,5-triphos-
phate (IP3), protein kinase C and Ca2þ (Christ et al., 1993;
1995; Wehling et al., 1995). The identity of the receptor
responsible for the nongenomic effects is currently not known.
The effects of aldosterone in the heart include inflammation,
fibrosis, positive inotropy and coronary vasodilation (Camp-
bell et al., 1993; Sun et al., 1993; Moreau et al., 1996; Barbato
et al., 2002; Sun et al., 2002). Not all studies confirm these
findings, however, nor has consensus been obtained on the
receptor(s) mediating these effects. This is due to the fact that
in some cases the results were obtained using only one
concentration of aldosterone with or without spironolactone
(Brilla et al., 1994; Moreau et al., 1996; Barbato et al., 2002),
whereas in others the study involved in vivo treatment with
spironolactone, which does not allow conclusions on the local
cardiac effects of this drug (Rochetaing et al., 2003).
In the present study, we set out to distinguish the genomic
and nongenomic effects of aldosterone in the heart. Using the
isolated perfused rat Langendorff heart preparation, we
evaluated the effects of aldosterone on left ventricular pressure
(LVP) and coronary flow (CF), as well as its effects on infarct
size and recovery of LVP and CF following ischaemia and
reperfusion. In cultured neonatal rat cardiomyocytes and
fibroblasts, we determined the effects of aldosterone on DNA
and collagen synthesis. These effects were compared to the
effects of aldosterone on DNA synthesis in aortic vascular
smooth muscle cells (VSMCs). Genomic and nongenomic
effects were distinguished using the MR receptor antagonist
spironolactone. We also investigated the effects of Ang II,
alone and in combination with aldosterone, because recent
studies suggest that aldosterone exerts its effects, at least in
part, via Ang II and/or Ang II type 1 (AT1) receptors (Mazak
et al., 2004; Michel et al., 2004; Xiao et al., 2004).
Methods
Drugs
Ang II, aldosterone, spironolactone and trypan blue were
purchased from Sigma-Aldrich Chemie BV, Zwijndrecht, The
Netherlands. Stock solutions of aldosterone (10mM) and
spironolactone (1mM) were prepared in ethanol. All other
chemicals were dissolved in distilled water.
Ethical approval
All experiments were performed under the regulations of the
Animal Care Committee of the Erasmus MC, in accordance
with the ‘Guiding Principles in the Care and Use of
Laboratory Animals’ as approved by the American Physiolo-
gical Society.
Experiments in Langendorff hearts
Male Wistar rats (n¼ 66, weight 300–340 g), obtained from
Harlan, Zeist, The Netherlands, were anaesthetised with
sodium pentobarbital (60mg kg�1, i.p.). Hearts were rapidly
excised and cooled in ice-cold Krebs–Henseleit solution
(composition in mM: NaCl 125, KCl 4.7, NaHCO3 20,
NaH2PO4 0.43, MgCl2 1.0, CaCl2 1.3 and D-glucose 9.1; pH
7.4) until contractions stopped, and prepared for Langendorff
perfusion. Continuously carbogen-gassed (95% O2/5% CO2)
Krebs–Henseleit solution at 371C was perfused immediately
after cannulation of the aorta, at a constant perfusion pressure
of 80mmHg. A water-filled latex balloon was placed in the left
ventricle via the left atrium to measure LVP. The volume of the
balloon was adjusted to achieve a stable left ventricular end-
diastolic pressure (LVEDP) of 5mmHg during initial equili-
bration, and this volume was maintained throughout the
experiment. Hearts were paced at 350 beatsmin�1. CF was
measured by an inline flow probe (Transonic Systems, Ithaca,
NY, U.S.A.).
After a stabilization period of 15min, 100ml bolus injections
were applied to construct dose–response curves to Ang II,
vehicle (ethanol), aldosterone and/or spironolactone. In a
second series of experiments, we evaluated the effects of
aldosterone and spironolactone during ischaemia and reperfu-
sion. Hearts were subjected to 45min left anterior descending
coronary artery occlusion, followed by 3 h of reperfusion.
Occlusion was preceded by either no treatment (control),
preconditioning (15min of occlusion followed by 10min of
reperfusion), or a 15-min exposure to vehicle (0.01% ethanol,
final concentration in perfusion buffer), aldosterone (100 nM)
or spironolactone (100 nM). Vehicle, aldosterone and spirono-
lactone remained present in the perfusion buffer throughout
the remainder of the experiment. After the 3-h reperfusion
period, area at risk and infarct size were determined as
described before (Schoemaker & van Heijningen, 2000).
Experiments in cells
Primary cultures of neonatal Wistar rat (Harlan) ventricular
cardiomyocytes and fibroblasts were prepared as described
before (van Kesteren et al., 1997; Saris et al., 2002). Briefly,
ventricles from newborn 1–3-day-old Wister rats were minced
and cells of ventricles were isolated by eight subsequent
trypsinization steps. Nonmyocytes were separated from
myocytes by differential preplating. Myocytes were seeded in
24-well plates at 1.5–1.75� 105 cells cm�2, giving a confluent
monolayer of spontaneously beating cells after 24 h. The
preplated cells (fibroblast fraction) were passaged after 4 days
to 24-well plates at 0.75� 105 cells cm�2. Myocytes and
fibroblasts were maintained at 371C and 5% CO2–95% air in
DMEM and Medium 199 (4 : 1), supplemented with 5% foetal
calf serum (FCS), 5% horse serum, 100U penicillinml�1 and
100 mg streptomycinml�1.
VSMCs were isolated from Sprague–Dawley rat thoracic
aortas by enzymatic digestion as described previously (Haller
et al., 1994). Cells were grown in SmGM-2 (Clonetics,
Verviers, Belgium) supplemented with 5% FCS, and were
passaged by harvesting with 0.05% trypsin/0.53mM EDTA
and seeding into 75 cm2 flasks. For experiments, cells between
passages 3 and 8 were seeded in 24-well plates and grown to
confluency at 371C and 5% CO2–95% air.
Experiments were performed after the cells had been serum-
deprived for at least 1 day. Before the start of each experiment,
cells were rinsed three times with 1ml warm (371C) serum-free
medium. Next, the cells were incubated for 24 h at 371C with
400 ml serum-free medium (supplemented with 1% bovine
serum albumin (BSA) in the case of myocytes and fibroblasts),
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and containing Ang II, vehicle (0.1% ethanol), aldosterone
and/or spironolactone. DNA and collagen synthesis rates were
determined in duplicate by quantifying [3H]thymidine and
[3H]proline incorporation, respectively, during the last 6 h of
the above 24-h incubation period. Total cellular protein and
DNA were quantified after solubilization as described before
(van Kesteren et al., 1997), using BSA and salmon sperm as
standard, respectively.
Data analysis
Data are expressed as mean7s.e.m. and are shown either as
percent change from baseline (LVP, CF) or relative to control
values (DNA and collagen synthesis rates). Dose–response
curves were analysed as described before (Tom et al., 2002)
to obtain pEC50 (�10log EC50) values. Statistical analysis was
carried out by ANOVA, followed by post hoc evaluation
according to Tukey. P-values o0.05 were considered sig-
nificant.
Results
Experiments in Langendorff hearts
Baseline values of LVP and CF were 8071.4mmHg (n¼ 60)
and 1270.3mlmin�1, respectively. Ang II (n¼ 6) and aldos-
terone (n¼ 6) dose-dependently increased LVP (pEC50
7.470.3 and 9.870.4, respectively) and reduced CF (pEC50
8.070.7 and 8.770.6, respectively) (Figure 1). Maximum
effects of Ang II occurred within 2–3min and lasted 5–6min,
whereas the maximum effects of aldosterone occurred within
1–2min and lasted o2min. Spironolactone (n¼ 6) did not
significantly affect LVP or CF (Figure 1). Vehicle (n¼ 6) also
did not affect CF, and decreased LVP at the highest two
concentrations that were evaluated (corresponding to 0.1 and
1% ethanol in the bolus injection fluid, respectively).
Spironolactone (10 mM, n¼ 6) reduced the effect of aldosterone
on LVP, without changing its pEC50. Spironolactone did not
alter the effects of aldosterone on CF.
In six (three control hearts, two aldosterone-pretreated
hearts and one vehicle-pretreated heart) of the 36 hearts that
were exposed to ischaemia plus reperfusion, we could not
determine LVP and CF during reperfusion because of severe
ventricular arrhythmias. These hearts were therefore excluded
from the analysis. In the remaining 30 hearts, occlusion of the
left anterior descending coronary artery reduced LVP to
E30mmHg and decreased CF by approximately 50%
(Table 1). In control hearts (n¼ 6), LVP and CF increased
rapidy during the reperfusion phase (Table 1), stabilizing after
approximately 20min at 4473 and 86713% of pre-ischaemia
values (Figure 2). LVEDP increased to 2375mmHg. Pre-
treatment with aldosterone (n¼ 6) or vehicle (n¼ 6) did not
affect LVP and CF recovery, nor did it prevent the rise in
LVEDP. Preconditioning (n¼ 6) as well as pretreatment with
spironolactone (n¼ 6) significantly enhanced recovery of LVP
(Po0.05), but not of CF (Table 1 and Figure 2). Both
procedures tended to reduce the rise in LVEDP (P40.05).
Ventricular fibrillation occurred within the first 10min of
reperfusion of all control hearts (Table 1). The incidence of
fibrillation was reduced in hearts exposed to preconditioning
or spironolactone, but not in hearts pretreated with aldoster-
one or vehicle. The area at risk was identical in all hearts
(Table 1). Infarct size (expressed as a percentage of the area at
risk) was 6872% in control hearts (Figure 2). Preconditioning
and spironolactone similarly reduced infarct size (Po0.05),
whereas infarct sizes in aldosterone- and vehicle-treated hearts
were not different from control.
Experiments in cells
In cardiomyocytes, aldosterone decreased [3H]thymidine
incorporation in a concentration-dependent manner (pEC50
6.670.4, n¼ 9; Figure 3). Spironolactone (n¼ 9) did not affect
[3H]thymidine incorporation, and reversed the effects of
1mmol l�1 aldosterone in a concentration-dependent manner
(pEC50 6.570.3, n¼ 9). This indicates that the effects of
aldosterone on DNA synthesis depend on MR activation. Ang
II (100 nM; n¼ 7) increased [3H]thymidine incorporation by
5176% (Po0.05), and aldosterone concentration-depen-
dently inhibited this effect (n¼ 7). Vehicle did not affect
[3H]thymidine incorporation (10076%, n¼ 9). Total protein
(133713mg per well) and total DNA (5.370.5 mg per well)
contents of myocytes were not affected by any of the
(ant)agonists, their combination or vehicle (data not shown).
In cardiac fibroblasts, aldosterone decreased [3H]proline
incorporation in a concentration-dependent manner (pEC50
7.770.7, n¼ 4; Figure 3). Spironolactone (n¼ 4) did not
affect [3H]proline incorporation, and reversed the effects of
1mmol l�1 aldosterone in a concentration-dependent manner
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Figure 1 Left panels: Effect of Ang II, spironolactone (spi) and
vehicle on CF and LVP. Right panels: Effect of aldosterone on CF
and LVP in the absence (control) and presence of 10 mM
spironolactone. Values (mean7s.e.m., n¼ 6) are expressed as
percentage change from baseline.
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(pEC50 6.670.7, n¼ 4). This indicates that the effects of
aldosterone on collagen synthesis depend on MR activation.
Ang II (100 nM; n¼ 4) increased [3H]proline incorporation by
3377% (Po0.05), and aldosterone concentration-depen-
dently inhibited this effect (n¼ 4). Vehicle did not affect
[3H]proline incorporation (9872%, n¼ 4). Total protein
(64714mg per well) and total DNA (2.170.2mg per well)
contents of fibroblasts were not affected by any of the
(ant)agonists, their combination or vehicle (data not shown).
In aortic VSMCs, aldosterone decreased [3H]thymidine
incorporation in a concentration-dependent manner (pEC50
7.470.4, n¼ 7; Figure 4). Spironolactone (n¼ 7) did not affect
[3H]thymidine incorporation, and partially reversed the effects
of 1mmol l�1 aldosterone. Ang II (100 nM; n¼ 7) did not
significantly affect [3H]thymidine incorporation. However, in
the presence of 10 nM aldosterone, it increased [3H]thymidine
incorporation by 56715% (Po0.01). Higher concentrations
of aldosterone decreased [3H]thymidine incorporation in the
presence of Ang II, to the same degree as under baseline
conditions (Figure 4). Vehicle did not affect [3H]thymidine
incorporation (111722%, n¼ 7). Total protein (138714mg
per well) and total DNA (4.170.4mg per well) contents of
VSMCs were not affected by any of the (ant)agonists, their
combination or vehicle (data not shown).
Discussion
The present study distinguishes both MR (‘genomic’)- and
non-MR (‘nongenomic’)-mediated effects of aldosterone in the
rat heart. Genomic effects include inhibition of DNA synthesis
in cardiomyocytes, inhibition of collagen synthesis in cardiac
fibroblasts, and deleterious cardiac effects (including fibrilla-
tion) during ischaemia and reperfusion. Nongenomic effects
include coronary vasoconstriction and, most likely, positive
inotropy. The nongenomic effects of aldosterone on vasocon-
striction and inotropy parallel the effects of Ang II on these
parameters, whereas the genomic effects on growth and
remodelling counteract those of Ang II.
Nongenomic effects
At first sight (Figure 1), it appears that spironolactone blocks
the inotropic effects of aldosterone, thus suggesting that these
effects are mediated via MR activation. However, in contrast
with this conclusion, the inotropic effects occurred within
minutes, whereas MR-induced effects usually occur after
hours. Furthermore, the inotropic effects occurred at the same
Table 1 Area at risk, fibrillation incidence, and haemodynamic parameters at baseline, after 45min of coronary artery
occlusion (‘ischaemia’), and during reperfusion
Parameter Pretreatment
None Preconditioning Vehicle Aldosterone Spironolactone
LVEDP (mmHg)
Baseline 5.270.2 5.170.2 5.270.2 5.370.3 5.270.2
Ischaemia 9.771.3 8.371.5 7.871.5 7.371.0 5.770.5
Reperfusion 2375.3 1472.0 33710 2477.2 11713
LVP (mmHg)
Baseline 7576.9 8272.3 8273.1 8173.7 8172.7
Ischaemia 2772.4 2873.8 3073.1 3372.6 3473.4
Reperfusion 3173.2 5071.8* 3973.5 3874.9 5274.9*
CF (mlmin�1)
Baseline 1370.8 1370.9 1370.9 1170.9 1271.1
Ischaemia 7.770.8 6.271.5 6.170.8 4.070.3 6.770.7
Reperfusion 1071.0 1170.7 1072.1 7.970.5 9.970.7
Area at risk (%) 5073 5273 5273 5273 5373
Fibrillation incidence 6/6 2/6* 5/6 6/6 2/6*
Data are mean7s.e.m. of six experiments. *Po0.05 vs no pretreatment. LVEDP, left ventricular end-diastolic pressure; LVP, left
ventricular pressure; CF, coronary flow.
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Figure 2 Infarct size (left panel) and recovery of LVP (right panel)
in hearts that were subjected to 45min left anterior descending
coronary artery occlusion, followed by 3 h of reperfusion, after
either no pretreatment (C, control), preconditioning (PC, 15min of
occlusion followed by 10min of reperfusion), or a 15-min exposure
to vehicle (Veh), 100 nM aldosterone (Aldo), or 100 nM spironolac-
tone (Spi). Values are mean7s.e.m. of six experiments. *Po0.05 vs
control.
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(subnanomolar) aldosterone concentration range as the non-
genomic effects on CF, that is, at levels that were approxi-
mately 100 times lower than the levels required to induce MR-
induced effects in cultured cardiac cells. Finally, spironolac-
tone did not alter aldosterone potency; it only reduced
aldosterone efficacy. With regard to the latter, it is important
to note that both aldosterone and spironolactone were
dissolved in ethanol. Ethanol, like methanol, decreases
contractility in a concentration-dependent manner (Tom
et al., 2001). The spironolactone concentration that we and
others (Moreau et al., 1996) used (10 mM) corresponds with an
ethanol concentration of 1% in the 100ml bolus injection, and
thus the ‘blocking’ effects of spironolactone may in reality
represent ethanol-induced physiological antagonism of aldos-
terone. Owing to the negative inotropic effect of ethanol, the
positive inotropic effect of aldosterone in the present study is
probably underestimated. Moreover, when correcting for the
ethanol-induced negative inotropic effect, our study would
reveal a positive inotropic action for spironolactone as well,
thereby further arguing against the MR as the mediator of the
inotropic effect of aldosterone. This conclusion is in full
agreement with a previous report in the isolated working rat
heart, where 10nM spironolactone increased contractility on
top of 10 nM aldosterone (Barbato et al., 2002). The ethanol
concentration in the perfusion fluid in that study was
maximally 0.036%. The ethanol concentration in the perfusion
fluid in our experimental setup, at a CF of E12mlmin�1, was
most likely o1%, but 40.036%. Propanediol has also been
used to dissolve aldosterone and spironolactone. This solvent,
however, similarly reduces inotropy, and thus the ‘blocking’
effect of 10mM spironolactone (dissolved in propanediol)
towards 10nM aldosterone observed in an earlier study in the
isolated rat heart (Moreau et al., 1996) may well be explained
on the basis of the same physiological antagonism described
above for ethanol. Taken together therefore, the inotropic effect
of aldosterone is unlikely to be mediated via MR activation.
Positive inotropy favours coronary vasodilatation, and this
may explain why Barbato et al. (2002), in the isolated working
rat heart, observed vasodilation during a 45% increase in
contractility in response to 10nM aldosterone, as opposed to the
aldosterone-induced vasoconstriction observed in the present
study. In our Langendorff setup, the inotropic response to
aldosterone was of modest proportion (maximallyE10%) and
this may not have been sufficient to result in a rise in CF. Rapid
nongenomic vasoconstrictor effects of aldosterone have been
described before (Schmidt et al., 2003), and hyperaldosteronism
in hypertensive subjects results in impaired endothelium-
dependent flow-mediated vasodilation (Nishizaka et al., 2004).
Ang II, like aldosterone, and in agreement with previous
studies (de Lannoy et al., 1997; 1998; Libonati et al., 1997;
Mu¨ller et al., 1998) caused coronary vasoconstriction and
increased inotropy. The effects of Ang II were larger, occurred
later and lasted longer than the effects of aldosterone on these
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Figure 3 Effect of aldosterone (top panels) and spironolactone
(bottom panels) on [3H]thymidine incorporation (DNA synthesis) in
myocytes and on [3H]proline incorporation (collagen synthesis) in
fibroblasts, either at baseline or in the presence of 100 nM Ang II or
1 mM aldosterone. Values (mean7s.e.m., n¼ 4–9) are expressed
relative to control; C refers to the response in the absence of
aldosterone or spironolactone. Ang II increased [3H]thymidine
incorporation by 5176% (Po0.05). Aldosterone decreased [3H]thy-
midine incorporation, both in the presence of Ang II (to 3774% of
control, Po0.001) and at baseline (to 3773% of control, Po0.001).
Ang II increased [3H]proline incorporation by 3377% (Po0.05),
and aldosterone fully reversed this effect, as evidenced by the
absence of Ang II-induced effects on collagen synthesis (P¼NS
vs control) at aldosterone concentrations of 1 mM and higher. At
baseline, aldosterone decreased [3H]proline incorporation to
6275% (Po0.05) of control. Spironolactone did not exert effects
at baseline, and, at a concentration of 10 mM, reversed the
aldosterone-induced decreases in DNA and collagen synthesis to
levels that were not significantly different from control.
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Figure 4 Effect of aldosterone (left panel) and spironolactone
(right panel) on [3H]thymidine incorporation in vascular smooth
muscle cells, either at baseline or in the presence of 100 nM Ang II or
1 mM aldosterone. Values (mean7s.e.m., n¼ 7) are expressed relative
to control; C refers to the response in the absence of aldosterone or
spironolactone. Ang II did not significantly affect [3H]thymidine
incorporation. On top of Ang II, aldosterone exerted a biphasic
effect: at a concentration of 10 nM, it increased [3H]thymidine
incorporation to 156715% of control (Po0.01), and at higher
concentrations it decreased [3H]thymidine incorporation to 1475%
of control (Po0.001). At baseline, aldosterone did not affect
[3H]thymidine incorporation at concentrations up to 10 nM, whereas
at higher concentrations it decreased [3H]thymidine incorporation to
1376% of control (Po0.001). Spironolactone, at a concentration of
10 mM, partially blocked the effects of 1 mM aldosterone, as evidenced
by the fact that the aldosterone-induced effects at this spironolac-
tone concentration were still significantly different (Po0.05) from
control.
668 W. Chai et al Cardiac effects of aldosterone
British Journal of Pharmacology vol 145 (5)
Aldosterone effects in rat heart 
43
parameters. Owing to this difference in time course (which has
been noted before in cultured cells (Mazak et al., 2004)), we did
not attempt to study the combined effects of Ang II and
aldosterone on coronary vasoconstriction and inotropy. The
difference in time course suggests that separate mechanisms
underlie the contractile responses to Ang II and aldosterone, so
that additive effects and/or synergy might be expected following
combined application (Mazak et al., 2004; Michel et al., 2004).
Genomic effects
Spironolactone significantly improved the condition of the
heart following ischaemia and reperfusion, as evidenced by a
reduction in infarct size, incidence of fibrillation and LVEDP,
and an increase in LVP recovery. The protective effects of
spironolactone were comparable to those of preconditioning
(Schoemaker & van Heijningen, 2000), and they cannot be
contributed to ethanol, as in this part of the study we used a
spironolactone concentration of 100 nM, that is, a concentra-
tion that is sufficiently low to avoid the ethanol-induced
negative inotropic effects. Chronic in vivo treatment of rats
with spironolactone similarly improved the condition of the
heart when it was mounted in the Langendorff apparatus and
exposed to low-flow ischaemia (Rochetaing et al., 2003).
However, under those conditions it could not be concluded to
what extent the effects of spironolactone were of cardiac origin.
Our data now provide evidence that the beneficial effects of
MR blockade during ischaemia indeed originate in the heart.
There are several explanations for this finding. First, spirono-
lactone may prevent adverse MR-mediated effects of locally
synthesized aldosterone. Such effects include proarrhythmo-
genic actions (Tillmann et al., 2002) and increased synthesis of
oxygen radicals (Mazak et al., 2004). Second, spironolactone
might exert beneficial effects of its own, independently of
aldosterone, for example, it acts antiarrhythmogenic through
blockade of human Ether-a-Go-Go-Related gene (HERG)
Kþ channels (Caballero et al., 2003), and it inhibits calcium
entry through calcium channels (Cargnelli et al., 2001). The
lack of additional deleterious effects of aldosterone exposure,
in addition to the evidence for aldosterone synthesis in the
rat heart (Silvestre et al., 1998), particularly under ischemic
conditions (Silvestre et al., 1999), favours the concept that
spironolactone interferes with locally released aldosterone.
Aldosterone inhibited DNA and collagen synthesis in
cultured cardiac cells, and spironolactone blocked these
effects, thereby providing evidence for their MR-dependency.
The aldosterone concentrations required to inhibit DNA and
collagen synthesis were E100 times higher than the concen-
trations that induced vasoconstriction and positive inotropy.
On the one hand, this suggests that the effects in cultured cells
are indeed mediated via mechanisms/receptors different from
the constrictor and inotropic effects in the intact heart,
whereas, on the other hand, it is questionable whether such
high concentrations actually exist at tissue sites in vivo. High
aldosterone concentrations are required to activate cardiac
MRs, because the levels of 11b-hydroxysteroid dehydrogenase
2 in the heart are relatively low (Lombe`s et al., 1995). This
enzyme converts the MR-binding glucocorticoids cortisol and
corticosterone (which circulate at concentrations that are
several orders of magnitude higher than those of aldosterone)
into the their non-MR-binding metabolites cortisone and 11-
dehydrocorticosterone. Normally, glucocorticoid binding to
MRs in cells maintained under serum-free conditions should
not occur, unless the receptors are still occupied by gluco-
corticoids bound to the cells during their incubation with
serum. Such cell binding also underlies the presence of renin–
Ang system components in cardiomyocytes under serum-free
conditions (van Kesteren et al., 1999).
The inhibitory effects of aldosterone on cardiac growth and
remodelling contrast with in vivo studies showing cardiac
fibrosis following long-term aldosterone exposure (Sun et al.,
1993; 2002). However, fibrosis is also observed following
conditional expression of an antisense mRNA of the MR in
the mouse heart (Beggah et al., 2002). Thus, the effect of
circulating aldosterone may differ from the effect of locally
synthesised aldosterone, and myocardial fibrosis is unlikely to
be a direct effect of aldosterone on cardiac fibroblasts. The
effects of aldosterone on DNA and collagen synthesis oppose
the effects of Ang II on these parameters, and this may explain
why aldosterone, on top of Ang II, exerts a modulatory role in
the development of cardiac hypertrophy in humans (Osterop
et al., 1998; Deinum et al., 2001; Tsybouleva et al., 2004).
Finally, we verified the response of aldosterone on DNA
synthesis in aortic VSMCs. When given at baseline, aldoster-
one reduced [3H]thymidine incorporation, and this effect was
blocked, at least in part, by spironolactone. Thus, as in
cardiomyocytes, aldosterone inhibited DNA synthesis in an
MR-dependent manner. The fact that spironolactone did not
completely block the effect of aldosterone suggests that other
(nongenomic) pathways may also have played a role. Alter-
natively, the highest spironolactone concentration in this study
(10mM) may have been insufficient to fully prevent the almost
complete inhibition of DNA synthesis in the presence of 1mM
aldosterone in VSMCs. In cardiomyocytes, the prevention at
this concentration of spironolactone was more complete
(allowing DNA synthesis to return to levels that were not
significantly different from control), possibly because the effect
of aldosterone in these cells was of more modest proportion.
In the presence of Ang II, aldosterone exerted a biphasic
effect on DNA synthesis in VSMCs: at low concentrations
(nM range) it enhanced the response to Ang II, and at high
concentrations (mM range) it blocked the response to Ang II.
Such a biphasic, Ang II-dependent, [3H]thymidine incorpora-
tion response to aldosterone has been noted before in rat
VSMCs (Xiao et al., 2004). The mechanism mediating the
enhanced response is not known, but may involve upregulation
of AT1 receptors (Xiao et al., 2004). The fact that it occurred
at nM concentrations of aldosterone is suggestive for a
nongenomic phenomenon.
Conclusion
Aldosterone induces positive inotropic and vasoconstrictor
effects in a nongenomic manner, and may thus potentiate the
effects of Ang II on inotropy and vasoconstriction. Aldoster-
one reduces DNA and collagen synthesis via MR activation,
and antagonises the Ang II-induced increases in these
parameters. MR blockade reduces infarct size and restores
cardiac function following a 45-min period of ischaemia to a
similar degree as preconditioning. The cardiac MR-mediated
effects may help to explain, at least in part, the beneficial
actions of spironolactone and other MR antagonists on top of
ACE inhibition in heart failure (Pitt et al., 1999; 2003).
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Summary
Mineralocorticoid receptor (MR) antagonism with eplerenone reduces mortality in heart 
failure, possibly due to blockade of the deleterious effects of cardiac aldosterone. To 
investigate these effects, rat Langendorff hearts were exposed to aldosterone and/or 
eplerenone under normal and ischemic conditions. Under normal conditions, aldosterone 
increased left ventricular pressure (LVP) and decreased coronary flow. Eplerenone did 
not block these effects. Eplerenone reduced infarct size (from 68±2 to 53±4%, P<0.05) 
and increased LVP recovery (from 44±2% to 60±5%, P<0.05) after 45 minutes of 
coronary artery occlusion and 3 hours of reperfusion, whereas aldosterone did not affect 
these parameters. To verify the origin of cardiac aldosterone, hearts were perfused with 3-
30 nmol/L aldosterone, and either frozen immediately or exposed to washout. Without 
washout, cardiac aldosterone was 1.5 times aldosterone in coronary effluent (CE), i.e. too 
high to be explained on the basis of its presence in extracellular fluid. The cardiac levels 
of aldosterone correlated with its CE levels (r=0.81, P<0.01), and both were unaffected 
by eplerenone. During washout, tissue aldosterone disappeared monophasically (t½ 9±1 
min), and CE aldosterone disappeared biphasically (t½’s 1±0 and 8±1 min, respectively). 
During buffer perfusion, cardiac aldosterone was at or below the detection limit. In 
conclusion, eplerenone improves the condition of the heart following ischemia and 
reperfusion. This does not relate to interference with the inotropic and vasoconstrictor 
effects of aldosterone. The majority of cardiac aldosterone, if not all, is derived from the  
circulation. The rapid, MR-independent, kinetics of aldosterone suggests that its 
accumulation in the heart involves cell surface binding rather than internalization. 
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Introduction
Two large clinical trials in patients with heart failure have recently shown that the 
mineralocorticoid receptor (MR) antagonists spironolactone and eplerenone improve 
morbidity and mortality on top of ACE inhibition [1,2]. In particular, a reduction in the 
rate of sudden death was observed. The mechanism responsible for this favorable effect is 
not entirely understood. It may involve changes in Na+/K+ homeostasis and/or myocardial 
fibrosis inhibition. In addition, conditional MR overexpression in the mouse heart, in the 
absence of aldosteronemia, was recently shown to result in severe arrhythmias [3]. Thus, 
cardiac MR may also trigger arrhythmias directly.  
 In support of this possibility, spironolactone improved electrophysiological
parameters in subjects with heart failure [4], and, in combination with the ACE inhibitor 
fosinopril, reduced the arrhythmic score post-myocardial infarction [5]. Since 
spironolactone is a non-specific MR antagonist, these effects do not necessarily involve 
MR [6]. Spironolactone also reduced infarct size and improved the recovery of left 
ventricular pressure following 45 minutes of global ischemia in the isolated perfused rat 
heart [7]. Interestingly, spironolactone did not block aldosterone-induced 
vasoconstriction, which worsens cardiac contractile and metabolic function in the 
ischemic heart [8,9]. It also did not prevent the inotropic effects of aldosterone in the 
heart [7,10], and, if anything, exerted inotropic effects of its own, independently of 
aldosterone.
 The aldosterone concentrations required to exert the above inotropic and 
vasoconstrictor effects are in the nanomolar range [7,9,10]. In the heart, it has been 
proposed that the presence of such high levels depend on local synthesis of aldosterone, 
although not all studies agree on this issue [11-13]. Across the human coronary vascular 
bed, both release and uptake of aldosterone have been observed [14,15].
 In the present study, using the isolated perfused rat Langendorff heart, we first 
investigated whether the new and more selective MR antagonist eplerenone exerts the 
same cardioprotective effects as spironolactone, in order to further unravel whether these 
effects are MR-mediated. Secondly, we studied the cardiac uptake and washout of 
circulating aldosterone, to determine whether eplerenone, if exerting a MR-dependent 
effect, interferes with locally synthesized or blood-derived aldosterone.
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Methods
Drugs
Aldosterone was purchased from Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands. Eplerenone was a kind gift of Pfizer, Capelle a/d IJssel, The Netherlands. 
Stock solutions of aldosterone (10 mmol/L) and eplerenone (10 mmol/L) were prepared 
in ethanol.
Ethical Approval 
All experiments were performed under the regulations of the Animal Care Committee of 
the Erasmus MC, in accordance with the “Guiding Principles in the Care and Use of 
Laboratory Animals” as approved by the American Physiological Society.  
Experiments in Langendorff Hearts 
Male Wistar rats (n=75, weight 300-420 g), obtained from Harlan, Zeist, The 
Netherlands, were anaesthetised with sodium pentobarbital (60 mg/kg, i.p.). Hearts were 
rapidly excised and cooled in iced-cold Krebs-Henseleit solution (composition in 
mmol/L: NaCl 125, KCl 4.7, NaHCO3 20, NaH2PO4 0.43, MgCl2 1.0, CaCl2 1.3 and D-
glucose 9.1; pH 7.4) until contractions stopped, and prepared for Langendorff perfusion. 
Continuously carbogen-gassed (95% O2 / 5% CO2) Krebs-Henseleit solution at 37C was 
perfused immediately after cannulation of the aorta, at a constant perfusion pressure of 
80 mmHg. A water-filled latex balloon was placed in the left ventricle via the left atrium 
to measure LVP. The volume of the balloon was adjusted to achieve a stable left 
ventricular end-diastolic pressure (LVEDP) of 5 mm Hg during initial equilibration, and 
this volume was maintained throughout the experiment. Hearts were paced at 350 
beats/minute. CF was measured by an in-line flow probe (Transonic Systems, Ithaca, NY, 
USA).
After a stabilization period of 15 minutes, 100 L bolus injections were applied to 
construct dose-response curves to aldosterone, vehicle (ethanol) and/or eplerenone. In a 
second series of experiments, we evaluated the effects of aldosterone and eplerenone 
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during ischaemia and reperfusion. Hearts were subjected to 45 minutes left anterior 
descending coronary artery occlusion, followed by 3 hours of reperfusion. Occlusion was 
preceded by either no treatment (control) or a 15-minute exposure 100 nmol/L 
aldosterone, 1 mol/L eplerenone or 100 nmol/L aldosterone + 1 mol/L eplerenone. 
Aldosterone and/or eplerenone remained present in the perfusion buffer throughout the 
remainder of the experiment. After the 3-hour reperfusion period, area at risk and infarct 
size were determined as described before. In a third series of experiments, we determined 
the uptake and disappearance of aldosterone in the heart. Blood (0.5 mL) was collected 
from the rats used in these experiments to measure the endogenous plasma levels of 
aldosterone. Hearts were perfused with 3, 10 or 30 nmol/L aldosterone or vehicle for 30 
minutes, in the absence or presence of 1 mol/L eplerenone. After the 30-minute 
perfusion period, the hearts were either frozen in liquid nitrogen or subjected to a 
washout period. One-minute samples of coronary effluent were collected prior to the 
perfusion, at 20 and 25 minutes after the start of the perfusion, and at 1, 2, 3, 4, 5, 10, 20 
and 30 minutes during the washout period. Aldosterone-perfused hearts that had been 
washed for 5 or 30 minutes were also frozen in liquid nitrogen.
Aldosterone Measurements 
Aldosterone was measured by solid-phase radioimmunoassay (DPC) in rat plasma, 
coronary effluent and cardiac tissue. To extract aldosterone from cardiac tissue, hearts 
were homogenized 1:2 in methanol. The homogenate was centrifuged at 3,000 rpm for 15 
minutes. Supernatants were then collected, vacuum dried, and dissolved in water prior to 
the assay. The detection limit was 25 pg/mL in plasma and coronary effluent, and 10 pg/g 
wet weight.
Data analysis 
Data are expressed as meanSEM. Dose-response curves were analyzed as described 
before16 to obtain pEC50 (-
10log EC50) values. Statistical analysis was by ANOVA, 
followed by post hoc evaluation according to Tukey. P values <0.05 were considered 
significant.
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Results
Haemodynamic studies 
Baseline values of LVP and CF were 80±1.6 mm Hg (n=66) and 11±0.2 mL/minute, 
respectively. Aldosterone (n=6) dose-dependently increased LVP (pEC50 9.80.4) and 
reduced CF (pEC50 8.70.6) (Figure 1). Eplerenone (n=6) also increased LVP (pEC50
8.91.3) without affecting CF (Figure 1). Vehicle (ethanol; n=6) did not affect LVP or 
CF. Eplerenone (0.1 or 1 mol/L, n=6 and 5, respectively) did not abolish the effects of 
aldosterone on LVP or CF.
Occlusion of the left anterior descending coronary artery reduced LVP to 30 mm 
Hg and decreased CF by approximately 50% (Table 1). In control hearts (n=6), LVP and 
CF increased rapidy during the reperfusion phase (Table 1), stabilizing after 
approximately 20 minutes at 443% and 8513% of pre-ischaemia values (Figure 2). 
LVEDP increased to 235 mm Hg. Pretreatment with aldosterone (n=6) did not affect 
LVP recovery, nor did it prevent the rise in LVEDP. Aldosterone tended to reduce CF 
recovery (P=NS, Figure 2). Pretreatment with eplerenone (n=6) significantly enhanced 
recovery of LVP (P<0.05), but not of CF (Table 1 and Figure 2). Eplerenone did not 
diminish the rise in LVEDP. Ventricular fibrillation occurred within the first 10 minutes 
of reperfusion of all control hearts (Table 1). Eplerenone, but not aldosterone, tended to 
reduce the incidence of fibrillation (P=NS). The area at risk was identical in all hearts 
(Table 1). Infarct size (expressed as a percentage of the area at risk) was 682% in 
control hearts (Figure 2). Eplerenone reduced infarct size (P<0.05), whereas the infarct 
size in aldosterone-treated hearts was not different from control. Combined exposure to 
eplerenone and aldosterone yielded similar results as eplerenone alone (Table 1, Figure 
2).
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Table 1 Haemodynamic parameters, area at risk, and fibrillation incidence at baseline, 
after 45 minutes of coronary artery occlusion (‘ischaemia’), and during reperfusion. 
Pretreatment Parameter 
None Aldo Eple Aldo+Eple 
Left ventricular end-diastolic pressure, mm Hg 
baseline 5.2±0.2 5.3±0.3 5.3±0.3 5.5±0.9 
ischaemia 9.7±1.3 7.3±1.0 7.3±1.0 6.7±1.5 
reperfusion 23±5.3 24±7.2 24±7.2 23±2.8 
Left ventricular pressure, mm Hg 
baseline 75±6.9 81±3.7 85±6.7 84±5.9 
ischaemia 27±2.4 33±2.6 36±3.3 36±3.0 
reperfusion 31±3.2 38±4.9 50±3.1* 49±3.5* 
Coronary flow, ml/minute 
baseline 13±0.8 11±0.9 12±0.9 12±0.7 
ischaemia 7.7±0.8 4.0±0.3 7.8±0.8 4.8±0.5 
reperfusion 10±1.0 7.9±0.5 11±1.3 11±1.6 
Area at risk, 
%
50±3 52±3 49±2 50±3 
Fibrillation 
incidence
6/6 6/6 4/6 5/7 
Data are meanSEM of 6-7 experiments. *, P<0.05 vs. no pretreatment. Aldo, 
aldosterone; Eple, eplerenone. 
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Figure 1 Left panels. Effect of eplerenone (eple) and vehicle on coronary flow and left 
ventricular pressure. Right panels. Effect of aldosterone on coronary flow and left 
ventricular pressure in the absence (control) or presence of 0.1 or 1 mol/L eplerenone. 
Values (meanSEM, n=6) are expressed as percentage change from baseline.
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Figure 2 Infarct size (left panel), recovery of left ventricular pressure (LVP) (middle 
panel), and recovery of coronary flow (CF) in hearts that were subjected to 45 minutes 
left anterior descending coronary artery occlusion, followed by 3 hours of reperfusion, 
after either no pretreatment (C, control) or a 15-minute exposure to 100 nmol/L 
aldosterone (A), 1 mol/L eplerenone (E) or 100 nmol/L aldosterone + 1 mol/L
eplerenone. Values are meanSEM of 6-7 experiments. * P<0.05 vs. control. 
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Kinetic studies 
Aldosterone levels in rat plasma were 8516 pg/mL (n=5). Aldosterone levels in the 
perfusate of vehicle-perfused hearts were <5815 pg/mL. In 5 out of 8 hearts these levels 
were below the detection limit. The cardiac aldosterone levels in vehicle-perfused hearts 
were <205 pg/g wet weight. In 1 out of 3 hearts this level was below the detection limit. 
The level of aldosterone in the coronary effluent during perfusion with 10 nmol/L 
aldosterone was 216187 pg/mL at 20 minutes, and 213299 pg/mL at 25 minutes
(p=NS, n=9), indicating that a steady state had been reached. The steady-state level in 
coronary effluent was 975% of the level in the perfusion buffer. After discontinuation of 
the aldosterone perfusion, aldosterone disappeared from the coronary effluent in a 
biphasic manner (n=6, Figure 3). The rapid phase had a t½ of 1.1±0.1 minute, and the 
slow phase had a t½ of 7.9±1.1 minutes. The cardiac tissue level of aldosterone, 
immediately after the 10 nmol/L aldosterone perfusion had been switched off, was 
2533±327 pg/g wet weight (n=3). During the washout phase, the tissue level decreased in 
a monophasic way, with a t½ of 9.1±1.0 minutes (Figure 3). Eplerenone, at a 
concentration of 1 mol/L, did not affect the steady-state tissue level reached following a 
30-minute perfusion with 10 nmol/L aldosterone (3471±197 pg/g wet weight, n=3; P=NS 
vs. without eplerenone). The cardiac tissue levels after a 30-minute perfusion with 3 or 30 
nmol/L aldosterone were 982±207 and 6720±941 pg/g wet weight (n=3 for both), 
respectively. Tissue levels (expressed per gram wet weight) closely correlated with 
coronary effluent levels (expressed per mL effluent) (r=0.81, P<0.01; Figure 4).
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Figure 3 Washout of aldosterone from coronary effluent (open circles) and cardiac tissue 
(closed circles) of the Langendorff heart after its perfusion with 10 nmol/L aldosterone 
for 30 minutes. Values are meanSEM of 3-6 experiments.
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Figure 4 Correlation between the levels of aldosterone in coronary effluent and cardiac 
tissue (r=0.81, P<0.01) following a 30-minute perfusion of the heart with 3, 10 or 30 
nmol/L aldosterone. 
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Discussion
The present study reveals no blocking effect of eplerenone towards the inotropic and 
vasoconstrictor effects of aldosterone in the rat Langendorff heart, thereby confirming 
that these effects are exerted in a ‘non-genomic’ manner, not involving MR [7,10]. In 
fact, eplerenone, like spironolactone, induced a modest inotropic effect of its own. The 
eplerenone concentration required to induce this inotropic effect was 3 orders of 
magnitude higher than the spironolactone concentration required to induce a similar 
effect [7,10], and thus, since the doses of both drugs are comparable, inotropic effects are 
less likely to occur during treatment with eplerenone than during treatment with 
spironolactone. Unlike spironolactone, eplerenone did not affect coronary flow. Possibly 
therefore, the spironolactone-induced effects on flow are mediated through a different 
receptor than its effects on contractility. The latter has been reported to involve increased 
myosin ATPase calcium sensitivity and diastolic calcium concentration [17]. 
Eplerenone protected the heart during ischaemia and reperfusion in a similar way 
as spironolactone (inducing a reduction in infarct size and improving LVP recovery), and 
therefore, this cardioprotective effect is most likely MR-mediated. It could relate to 
blockade of the proarrhythmogenic actions of aldosterone [3,18] and/or the aldosterone-
induced increase in oxygen radical synthesis [19]. If so, aldosterone was apparently still 
present in the isolated perfused rat Langendorff heart. It does not relate to the non-MR-
mediated coronary constrictor effects of aldosterone [8,9].
Aldosterone, at a concentration of 100 pmol/mL, did not further deteriorate the 
condition of the heart during the ischaemia + reperfusion procedure. Thus, the 
endogenous aldosterone levels in the heart were presumably <100 pmol/g, despite earlier 
reports by Silvestre et al. [11,20] describing such high aldosterone levels in the isolated 
perfused rat heart (50-500 pg/mg protein or, since 1 gram of tissue corresponds with 65-
100 mg protein [13,21], 10-150 pmol/g). Indeed, the cardiac tissue levels of aldosterone 
in our study were <20 pg/g. In some of our experiments, aldosterone was detectable in 
coronary effluent, obtained during the 30 minutes of perfusion with vehicle prior to the 
collection of the heart. Although this could reflect local synthesis of aldosterone [12], it 
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might also represent washout of blood-derived aldosterone that had accumulated in the 
heart in vivo.
To study the kinetics of uptake and washout of circulating aldosterone in the 
heart, we perfused the rat Langendorff heart with aldosterone, using concentrations 
corresponding with those in patients with severe heart failure [9,14,15]. Aldosterone 
perfusion resulted in a rapid rise of the cardiac aldosterone levels, independently of MR. 
After 30 minutes the tissue levels (expressed per g wet weight) were on average 1.5 times 
higher than the levels in coronary effluent (expressed per mL). Since the extracellular 
volume in this preparation is around 0.6 mL/g [22,23], the cardiac aldosterone levels are 
2-3 times higher than expected if the presence of aldosterone was limited to the 
extracellular fluid. Apparently therefore, aldosterone accumulates in a compartment other 
than extracellular fluid, e.g. it binds to cell surface receptors and/or reaches intracellular 
sites. In support of this concept, the washout of aldosterone after stopping the perfusion 
followed a biphasic pattern: a rapid phase corresponding with its disappearance from 
extracellular fluid [22,24], and a slow phase corresponding with its washout from a 
second compartment. This pattern resembles that of cardiac renin, which accumulates in 
extracellular fluid and binds to membrane receptors [22,25,26].  
Following perfusion of the Langendorff heart with aldosterone, the cardiac 
aldosterone levels correlated with the aldosterone levels in the perfusion buffer over a 
wide range, indicating a large capacity of the heart to accumulate aldosterone. 
Extrapolating this relationship to the plasma aldosterone levels in the rat (84 pg/mL) 
yields an in vivo cardiac tissue level of around 1.5 x 84  125 pg/g, in full agreement 
with the cardiac tissue levels reported by others in rats on a normal salt diet [13,27]. 
These levels are >6 times the level present after buffer perfusion. Apparently, the 15 
minutes of equilibration + 30 minutes of perfusion with aldosterone-free buffer prior to 
the collection of the heart were sufficient to wash away >85% of cardiac aldosterone. 
This is exactly what one would expect on the basis of a t½ of 8-9 minutes for the 
aldosterone disappearance from tissue sites, and thus it can be concluded that the majority 
of cardiac aldosterone, if not all, is taken up from the circulation.
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Perspective 
The present study complements previous studies on the disappearance of cardiac 
aldosterone following adrenalectomy [13,27] and simultaneously provides an explanation 
for the reduction in sudden death among patients taking MR antagonists [1,2]. On the one 
hand, the heart displays a large capacity to accumulate aldosterone. This explains why 
cardiac aldosterone in rats overexpressing human renin and human angiotensinogen 
(>99% of which is derived from the adrenal gland) can be up to 10-fold higher than in 
serum [27]. On the other hand, cardiac aldosterone disappears rapidly during perfusion 
with aldosterone-free buffer. This provides an explanation for the presence of aldosterone 
in the effluent of buffer-perfused hearts [12]. The rapid, MR-independent, kinetics of 
aldosterone observed in this study suggests that its cardiac accumulation involves cell 
surface binding rather than internalization followed by binding to intracellular MR. The 
cardioprotective effects of eplerenone during ischemia and reperfusion in the 
Langendorff preparation are most likely due to blockade of the MR-mediated 
arrhythmogenic effects [3] of this cell surface-bound aldosterone.
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Nongenomic Effects of Aldosterone in the Human Heart
Interaction With Angiotensin II
Wenxia Chai, Ingrid M. Garrelds, Rene´ de Vries, Wendy W. Batenburg,
Jorge P. van Kats, A.H. Jan Danser
Abstract—Aldosterone exerts rapid “nongenomic” effects in various nonrenal tissues. Here, we investigated whether such
effects occur in the human heart. Trabeculae and coronary arteries obtained from 57 heart valve donors (25 males; 32
females; 17 to 66 years of age) were mounted in organ baths. Aldosterone decreased contractility in atrial and ventricular
trabeculae by maximally 34�3% and 15�4%, respectively, within 5 to 15 minutes after its application. The protein
kinase C (PKC) inhibitor chelerythrine chloride, but not the mineralocorticoid receptor antagonists spironolactone and
eplerenone, blocked this effect. Aldosterone also relaxed trabeculae that were prestimulated with angiotensin II (Ang II),
and its negative inotropic effects were mimicked by hydrocortisone (at 10-fold lower potency) but not 17�-estradiol.
Aldosterone concentrations required to reduce inotropy were present in failing but not in normal human hearts. Previous
exposure of coronary arteries to 1 �mol/L aldosterone or 17�-estradiol (but not hydrocortisone) doubled the maximum
contractile response (Emax) to Ang II. �Emax correlated with extracellular signal-regulated kinase (ERK) 1/2
phosphorylation (P�0.01). Spironolactone and eplerenone did not block the potentiating effect of aldosterone. Studies
in porcine renal arteries showed that potentiation also occurred at pmol/L aldosterone levels but not at 17�-estradiol
levels�1 �mol/L. Aldosterone did not potentiate the �1-adrenoceptor agonist phenylephrine. In conclusion, aldosterone
induces a negative inotropic response in human trabeculae (thereby antagonizing the positive inotropic actions of Ang
II) and potentiates the vasoconstrictor effect of Ang II in coronary arteries. These effects are specific and involve PKC
and ERK 1/2, respectively. Furthermore, they occur in a nongenomic manner, and require pathological aldosterone
concentrations. (Hypertension. 2005;46:701-706.)
Key Words: aldosterone � mineralocorticoids � angiotensin � human
The steroid hormone aldosterone is synthesized in theadrenal cortex in response to angiotensin II (Ang II). The
primary cardiovascular effect of aldosterone has traditionally
been ascribed to regulation of electrolyte homeostasis and
extracellular fluid volume by promotion of sodium retention
and potassium excretion in the renal collecting duct. The
mechanism underlying this effect is of “genomic” nature (ie,
it involves binding to the intracellular mineralocorticoid
receptor [MR], followed by translocation of the steroid–
receptor complex to the nucleus, where this complex acts as
a transcription factor).
Two large clinical trials in patients with heart failure have
recently shown that MR antagonists improve morbidity and
mortality on top of angiotensin-converting enzyme inhibition.1,2
Because these beneficial effects could not be attributed solely to
blockade of the renal MR-mediated effects on blood pressure, it
has been proposed that aldosterone also exerts actions in extra-
renal tissues. Evidence for this concept is now readily available.
The nonrenal actions of aldosterone include inotropic effects in
the heart and vasoconstrictor as well as vasodilator effects in
various vascular beds.3–7 Unexpectedly, these effects occurred
within minutes rather than hours and could not always be
blocked by MR antagonists. Consequently, they are now known
as “nongenomic” effects of aldosterone. Some of these non-
genomic effects might in fact be exerted by aldosterone that has
been synthesized locally in the heart or vessel wall, although not
all studies agree on this possibility.8–10
The majority of the data on the nongenomic actions of
aldosterone have been obtained in animals. It was the aim of the
present study to investigate the nongenomic effects of aldoste-
rone in the human heart, focusing on trabeculae and coronary
arteries. To determine the specificity of the effects of aldoste-
rone, we also assessed the effects of 17�-estradiol and hydro-
cortisone. Furthermore, because aldosterone exerts its effects, at
least in part, via Ang II or Ang II type 1 (AT1) receptors,7,11 and
vice versa,10 we evaluated the interaction with Ang II in our
experimental setup. Finally, we looked into the mediators of the
effects of aldosterone in this study, focusing on those that have
already been coupled to the nongenomic actions of aldosterone
(protein kinase C [PKC], Ca2�, NO, and mitogen-activated
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protein kinases),3,6,7,10,12 and we determined the aldosterone
levels in normal and failing human hearts to put our findings into
a physiological perspective.
Methods
Tissue Collection
All studies were approved by the ethics committee of the Erasmus
MC. Human trabeculae, human coronary arteries (HCAs), and left
ventricular tissue were obtained from 57 heart-beating organ donors
(25 men and 32 women; 46�1 years of age [range 17 to 66]) who
died of noncardiac causes (46 cerebrovascular accident, 5 head
trauma, and 6 brain hypoxia) �24 hours before the heart was taken
to the laboratory. Hearts were provided by the Rotterdam Heart
Valve Bank after removal of the heart valves. Hearts were stored in
an ice-cold sterile organ-protecting solution after circulatory arrest.
After arrival at the laboratory, right atrial and left ventricular
trabeculae of�1-mm thickness were dissected and mounted in organ
baths.13 The trabeculae were paced at 1 Hz using electrical field
stimulation. Resting tension was set at 750 mg and 1950 mg for atrial
and ventricular trabeculae, respectively. Changes in contraction were
recorded with a force transducer. HCAs were removed and stored
overnight at 4°C, cut into segments of�4-mm length, and suspended
on stainless steel hooks in organ baths.13 Resting tension was set at
1.5 g. Left ventricular tissue pieces (5 to 10 g) were dissected from
the heart and frozen at �70°C. Left ventricular tissue (3 to 5 g) was
also obtained from 11 subjects (10 men and 1 woman; 48�4 years
of age [range 30 to 64]) with end-stage dilated cardiomyopathy
undergoing cardiac transplantation.14
Porcine renal arteries (PRAs) were removed from kidneys obtained at
the slaughterhouse. Vessels were stored overnight and suspended in
organ baths as described above. Resting tension was set at 2 g.
Trabeculae Studies
Trabeculae were allowed to equilibrate for �60 minutes, and organ
bath fluid was refreshed every 15 minutes during this period. Next,
a concentration-response curve (CRC) to norepinephrine was con-
structed to verify the viability of the tissue. After several washouts
and stabilization at baseline contractile force, CRCs to aldosterone,
spironolactone, eplerenone (a gift of Pfizer), hydrocortisone, their
solvent (ethanol), or 17�-estradiol (dissolved in water) were con-
structed, either at baseline or after prestimulation with forskolin
(dissolved in dimethylsulfoxide [DMSO]) or Ang II. To investigate
the mechanism of the aldosterone-induced effects, CRCs to aldoste-
rone were also constructed after preincubation with spironolactone,
eplerenone, the NO synthase inhibitor N�-nitro-L-arginine methyl
ester (L-NAME), the NO scavenger hydroxocobalamin (dissolved in
methanol), the guanylyl cyclase inhibitor ODQ, the PKC inhibitor
chelerythrine chloride (dissolved in DMSO), the intracellular Ca2�
blocker thapsigargin (dissolved in ethanol), or solvent. At the end of
each experiment, viability was verified with norepinephrine.
Vessel Studies
Viability was evaluated as described previously.13 Next, segments
were preincubated for 30 minutes with or without aldosterone,
17�-estradiol, spironolactone, eplerenone, or L-NAME, and CRCs to
Ang II, aldosterone, hydrocortisone, 17�-estradiol, solvent (ethanol),
or phenylephrine were constructed. Ang II CRCs were also con-
structed after completion of the CRCs to aldosterone, hydrocorti-
sone, 17�-estradiol, or solvent (ethanol) without refreshing the organ
bath fluid in between. To determine Ang II–induced extracellular
signal-regulated kinase (ERK) 1/2 activation, segments were col-
lected and frozen at �80°C within 10 minutes after exposure to the
highest Ang II concentration.
Biochemical Measurements
To determine ERK 1/2 phosphorylation, frozen HCA segments were
homogenized in Nonidet P-40 lysis buffer and kept on ice for 1 hour.
Next, they were centrifuged at 14 000g for 15 minutes at 4°C, and
the supernatants were collected and stored at �80°C until further
analysis. Protein was determined using the Bradford assay. Western
blotting was performed with 20 �g protein using phospho-ERK 1/2
and ERK antibodies (Westburg; 1:2000). Peroxidase-conjugated
secondary antibodies were from Pierce (1:5000). Blots were devel-
oped with the chemiluminescence substrate and visualized on Kodak
films. For semiquantification, the band obtained with Ang II alone
was defined as 100%.
Aldosterone was measured by solid-phase radioimmunoassay (Diag-
nostic Products Corporation) after its extraction from left ventricular
tissue. In short, tissue was homogenized 1:2 in methanol. The superna-
tant was collected after a 15-minute centrifugation at 3000 rpm at 4°C,
vacuum dried, and dissolved in water. The detection limit was 10 pg/g
wet weight.
Total renin (ie, renin plus prorenin) was measured by immunoradio-
metric assay in homogenized tissue after treatment with acid and
plasmin to activate prorenin.14
Data Analysis
Data are expressed as mean�SEM or geometric mean and range, and
n refers to the patient number. Trabeculae showing�25 mg response
to norepinephrine at the start or end of the experiment were excluded
from analysis. CRCs were analyzed as described previously to obtain
pEC50 (��log[EC50]) values.13 Aldosterone levels below the detec-
tion limit were taken to be equal to the detection limit. Statistical
analysis was by Mann–Whitney U test for unpaired observations,
paired t test, or 1-way ANOVA, followed by post hoc evaluation
according to Tukey. P�0.05 was considered significant.
Results
Trabeculae Studies
Baseline contractile forces were 164�11 mg and 233�15 mg
in atrial (n�29) and ventricular (n�15) trabeculae, respec-
tively. Norepinephrine increased contractile force in both
types of trabeculae in a concentration-dependent manner
(pEC50 6.2�0.1 and 6.1�0.1, respectively). The contractile
response to 10 �mol/L norepinephrine at the end of the
experiment was not different from that at the start
(�208�16% versus �205�11% in atrial trabeculae and
�196�20% versus �198�20% in ventricular trabeculae).
This indicates that tissue viability did not decrease during the
course of the experiment.
Aldosterone (pEC50 8.3�0.1; n�25) and hydrocortisone
(pEC50 7.6�0.2; n�5; P�0.01 versus aldosterone), but not
17�-estradiol (n�4), reduced contractility in atrial trabeculae
(Figure 1). The effects of aldosterone occurred within 5 to 15
minutes after its application. Aldosterone also reduced contrac-
tility in ventricular trabeculae (pEC50 8.1�0.5; n�7), although
its effects in this preparation were more modest than in atrial
trabeculae. The effects of spironolactone in atrial (pEC50
8.2�0.4; n�7) and ventricular (pEC50 8.7�0.1; n�6) trabeculae
were comparable to those of aldosterone. Eplerenone did not
exert effects in either atrial (n�7) or ventricular (n�4) trabec-
ulae, nor did solvent (n�4 and 6, respectively). In atrial
trabeculae, the negative inotropic effect of aldosterone after
prestimulation with either forskolin (n�6) or Ang II (n�6) was
identical to that at baseline. Aldosterone also relaxed forskolin-
prestimulated ventricular trabeculae (n�6). Without aldoste-
rone, the forskolin-induced increase in contractility remained
stable for �45 minutes (ie, the time required to construct an
aldosterone CRC).
Spironolactone (n�7), eplerenone (n�5), L-NAME (n�5),
hydroxocobalamin (n�5), ODQ (n�4), thapsigargin (n�5), and
solvent (methanol [n�4] or DMSO [n�5]) did not affect the
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aldosterone-induced negative inotropic effects (Figure 2), and
with the exception of spironolactone (see above), none of these
inhibitors affected baseline contractility. In contrast, cheleryth-
rine chloride (n�7) not only blocked the effect of aldosterone,
but tended to reverse it into a positive inotropic (P�NS)
response. Chelerythrine chloride did not affect baseline
contractility.
Vessel Studies
Ang II concentration-dependently constricted HCAs (pEC50
7.5�0.5; maximum contractile response [Emax] 29�7%;
n�13; Figure 3). Aldosterone (n�11), hydrocortisone
(n�11), 17�-estradiol (n�10), or solvent (ethanol; n�5), at
concentrations ranging from 1 pmol/L to 1 �mol/L, did not
affect baseline contractility in HCAs (data not shown).
However, when constructing an Ang II CRC after exposure to
aldosterone or 17�-estradiol (without refreshing the organ
bath fluid), Emax doubled to 55�11% and 51�14%, respec-
tively (P�0.05 versus control for both), with no change in
pEC50 (7.5�0.2 versus 7.5�0.2; Figure 3). Hydrocortisone
tended to induce a similar potentiation (P�NS; Figure 3),
whereas ethanol was without effect. Neither spironolactone
(n�8) nor eplerenone (n�8) blocked the effect of aldosterone
(Figure 3). The amount of phosphorylated ERK 1/2 tended to
be increased in the presence of 1 �mol/L aldosterone,
hydrocortisone, and 17�-estradiol (P�NS versus Ang II
alone; n�6 for all; Figure 4), with no change in the total
Figure 1. Inotropic effects of aldosterone (aldo), spironolactone
(spiro), eplerenone (eple), solvent (ethanol), 17�-estradiol, and
hydrocortisone in human right atrial (A and C) and left ventricular (B
and D) trabeculae at baseline (A and B) and after prestimulation
with 1 �mol/L forskolin (to 326�48% and 325�83% of baseline in
atrial and ventricular trabeculae, respectively) or 100 nmol/L Ang II
(to 32�7% of baseline; C and D). Data (mean�SEM of 4 to 25
experiments) are expressed as percent change from baseline con-
tractile force or from the contractile force after prestimulation.
Figure 2. Inotropic effects of aldosterone in atrial trabeculae in the
absence (E) or presence (F) of spironolactone (SPIRO; 10 �mol/L),
eplerenone (EPLE; 1 �mol/L), L-NAME (100 �mol/L), ODQ (10 �mol/
L), hydroxocobalamin (HC; 200 �mol/L), chelerythrine chloride (CHEL;
1 �mol/L), thapsigargin (THAPS; 1 �mol/L), or solvent (methanol or
DMSO). Data (mean�SEM of 4 to 7 experiments) were obtained in a
paired setup and have been expressed as percent change from base-
line contractile force. *P�0.05 vs control.
Figure 3. Contractions of HCAs to Ang II at baseline (control) or after
previous exposure to aldosterone (aldo), hydrocortisone (hydrocort), or
17�-estradiol (17�-estr; 1 pmol/L-1 �mol/L) with or without preincuba-
tion with 10 �mol/L spironolactone (Spiro) or 1 �mol/L eplerenone
(Eple). Data (mean�SEM; n�7 to 10) are expressed as a percentage
of the response to 100 mmol/L KCl. *P�0.05 vs control.
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amount of ERK 1/2. The increase in ERK 1/2 phosphoryla-
tion was limited to vessel segments displaying a large
increase in Emax, as evidenced by the significant correlation
between �Emax and ERK 1/2 phosphorylation (r�0.56;
P�0.01; Figure 4).
The effects of aldosterone, 17�-estradiol, and hydrocortisone
toward Ang II could be reproduced in PRAs: none of these
steroids affected baseline contractility at concentrations ranging
from 1 pmol/L to 1 �mol/L, and only previous exposure to
aldosterone and 17�-estradiol increased the Ang II Emax (n�9;
Figure 5). Therefore, PRAs were used to test whether the effects
of aldosterone and 17�-estradiol could also be observed at lower
concentrations. Preincubation with 17�-estradiol concentrations
�1 �mol/L did not result in potentiation (n�7; data not shown).
In contrast, the effects of aldosterone could be mimicked at
concentrations as low as 1 nmol/L (n�10; P�0.05) or, in the
presence of L-NAME, 1 pmol/L (n�4; P�0.05; Figure 5).
Furthermore, the potentiating effects were specific for Ang II
because preincubation with 1 nmol/L aldosterone did not affect
the phenylephrine CRC (n�4; Figure 5).
Aldosterone Levels in the Human Heart
Aldosterone levels in failing hearts (184 [range 10 to 4710]
pg/g; n�11) were �10-fold higher (P�0.02) than in normal
hearts (26 [range 10 to 481] pg/g; n�12). This parallels our
previous observations on cardiac renin.14 In fact, the levels of
renin in the heart correlated significantly with those of
aldosterone (r�0.71; P�0.05; Figure 6).
Discussion
The present study is the first to demonstrate nongenomic
actions of aldosterone in the human heart. Aldosterone
exerted a negative inotropic effect in atrial and ventricular
trabeculae at baseline and after prestimulation with the
adenylyl cyclase activator forskolin. This effect was long
lasting and, unlike the short-lasting negative inotropic effect
of bradykinin,15 did not involve the NO–cGMP pathway. The
PKC inhibitor chelerythrine chloride fully blocked the aldo-
sterone-induced negative inotropy, suggesting that it is me-
diated via the diacylglycerol–PKC signal transduction path-
way. Patch clamp studies in rabbit ventricular myocytes have
revealed that aldosterone affects Na�-K� pump activity via
�PKC,12 thereby providing a mechanism for the negative
inotropic response to aldosterone. The modest effect of
aldosterone in ventricles is in agreement with the fact that
atria have fewer sodium pumps than ventricles16 because low
expression enhances inotropic sensitivity.
The lack of effect of MR antagonists suggests that the
inotropic effects of aldosterone occur in an MR-independent
manner. In fact, as in the isolated perfused rat heart,4,5 spirono-
lactone exerted an inotropic effect that was comparable to that of
aldosterone, whereas the more selective MR antagonist
eplerenone did not. This further supports the MR independency
of the effects of aldosterone and spironolactone. However,
importantly, aldosterone and spironolactone exerted positive
inotropy in the rat heart,4,5 as opposed to the negative inotropy
observed here and in rabbit cardiomyocytes.12 Although this
may relate to species differences, alternative explanations must
be considered. First, inotropic effects in isolated trabeculae do
not necessarily parallel inotropic effects in intact hearts because
the latter also reflect responses on coronary flow. Second,
similar diametrically differing effects of aldosterone have been
observed on flow, either because such effects involve different
cells or because different second messengers are activated
depending on the experimental circumstances.5,6,12,17 Finally, the
consequences of PKC-induced regulation of Na�-K� pump
activity are tissue specific and range from stimulation to inhibi-
tion or no change.12,18
Figure 4. Left, Effects of Ang II on ERK
1/2 phosphorylation (p-ERK 1/2) and
total ERK 1/2 in HCAs at baseline (1;
control) or after previous exposure to
1 �mol/L aldosterone (2), hydrocortisone
(3), or 17�-estradiol (4). Top, 2 represen-
tative experiments; bottom, mean�SEM
of 6 experiments. Right, Correlation
(r�0.56; P�0.01) between the change in
Emax (� Emax) and the percent change in
Ang II–induced ERK 1/2 phosphorylation
in HCAs after previous exposure to aldo-
sterone (F), hydrocortisone (f), or 17�-
estradiol (�).
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Hydrocortisone mimicked the inotropic effects of aldosterone
at lower potency. This underlines the specificity of the aldoste-
rone effect. However, because glucocorticoids circulate at levels
that are several orders of magnitude higher than those of
aldosterone, the inotropic effects of aldosterone and glucocorti-
coids may occur simultaneously in vivo.
The aldosterone levels in failing human hearts were found to
be up to�5000 pg/g (corresponding with �15 nmol/L), that is,
high enough to allow the inotropic effects of aldosterone to
occur under pathological conditions in vivo. The levels in
normal hearts (�25 pg/g or �0.1 nmol/L) appeared to be too
low to exert inotropic effects. Although the origin of aldosterone
in the heart is still under debate,8 our observation that the cardiac
aldosterone levels correlate with the cardiac levels of renin
(which is exclusively of renal origin14), combined with previous
findings on cardiac extraction of aldosterone,19 suggest that at
least some cardiac aldosterone is of extracardiac origin.
The high renin levels in failing human hearts will result in
high local Ang II levels.20 In agreement with previous studies,21
Ang II was found to induce a modest (compared with norepi-
nephrine) positive inotropic effect. Aldosterone counteracted
this effect. This observation contrasts with the aldosterone-
induced potentiation of the vasoconstrictor effect of Ang II in
HCAs. Hydrocortisone and 17�-estradiol similarly potentiated
constriction, although significance was reached for 17�-estradiol
only. The magnitude of potentiation (ie, the increase in Emax)
correlated with the increase in the level of phosphorylated ERK
1/2, in full agreement with a previous study on steroid–Ang II
interaction in rat aortic vascular smooth muscle cells.7 None of
the steroids applied in the present study exerted a constrictor or
dilator effect of its own, and the Ang II–potentiating effects
became apparent only after constructing a CRC to the steroid.
Such construction requires 30 to 60 minutes, a time interval that
is insufficient to allow the AT1 receptor upregulation that
underlies the Ang II potentiation after a 24- to 48-hour exposure
to aldosterone and glucocorticoids.11,22
Studies in HCA smooth muscle cells have already indicated
that Ang II is capable of activating MR-mediated gene expres-
sion in an aldosterone-independent manner (suggesting MR
activation by post-translational modifications such as phosphor-
ylation).10 The present data extend this observation by demon-
strating functional synergy when applying aldosterone together
with Ang II. This synergy did not depend on MR activation, was
selective, and occurred at physiological aldosterone levels.
In the rat aorta,3 as well as the human forearm,6 aldosterone
has been reported to enhance vasoconstriction and vasodilation.
The latter was endothelium dependent, whereas the former could
only be observed during NO synthase blockade. The absence of
aldosterone-induced vasodilation in HCAs may relate to our
inability to observe endothelial NO release in these vessels.23
Limited NO release could also underlie the absence of a
vasodilator response to 17�-estradiol in HCAs. Despite the
higher incidence of stroke, myocardial infarction, and dementia
in postmenopausal women taking hormone replacement thera-
py,24 virtually all in vitro studies published so far claim that
estrogen induces vasodilation through endothelium-dependent
or endothelium-independent mechanisms.24 An alternative ex-
Figure 5. A, Contractions of PRAs to Ang II at baseline (control) or
after previous exposure to aldosterone, hydrocortisone, or 17�-
estradiol (1 pmol/L to 1 �mol/L). B, Contractions of PRAs to Ang II
at baseline (control) or after preincubation with 1 nmol/L aldoste-
rone. C, Contractions of PRAs to Ang II at baseline (control) or
after preincubation with 1 pmol/L aldosterone and 100 �mol/L
L-NAME. D, Contractions of PRAs to phenylephrine (PE) at base-
line (control) or after preincubation with 1 nmol/L aldosterone. Data
(mean�SEM; n�4 to 10) are expressed as a percentage of the
response to 100 mmol/L KCl. *P�0.05 vs control.
Figure 6. Correlation between the left ventricular levels of renin
and aldosterone (r�0.71; P�0.05) in 9 failing (E) and 2 (F) nor-
mal human hearts.
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planation for the absence of estrogen-induced vasodilation in
HCAs, at least in women, is the change in estrogen receptor
cellular localization during perimenopause.25 Furthermore, es-
trogen inactivates reactive oxygen species like the vasodilator
H2O226,27 and alters the AT1/AT2 receptor ratio.28,29 Both phe-
nomena will directly affect Ang II–induced vasoconstriction.
Perspectives
Aldosterone induces a negative inotropic response in human
trabeculae (thereby antagonizing the positive inotropic ac-
tions of Ang II) and potentiates the vasoconstrictor effect of
Ang II in HCAs. These effects occur in a rapid, nongenomic
manner, independently of MR, and involve PKC and ERK
1/2, respectively. Combined with the nonhemodynamic ef-
fects of aldosterone in cardiac tissue, which result in inflam-
mation and fibrosis,5,30 these data shed light on the wide
variety of actions of aldosterone in the heart. Future studies
should now address which receptor mediates the nongenomic
cardiac effects of aldosterone and to what degree these effects
occur in failing hearts. In view of the comparable beneficial
effects of spironolactone and eplerenone in heart failure,1,2
such studies should also critically evaluate the physiological
importance of the negative inotropic effect of spironolactone.
The many nongenomic, non–MR-mediated effects of aldo-
sterone suggest that aldosterone synthase inhibitors may yield
effects on top of MR blockade.
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Summary
The development of left ventricular (LV) hypertrophy in subjects with hypertrophic 
cardiomyopathy (HCM) is variable, suggesting a role for modifying factors such as 
angiotensin (Ang) II. Indeed, both the Ang II type 1 receptor (AT1-R) A/C
1166
polymorphism and the Ang II type 2 receptor (AT2-R) A/C
3123 polymorphism modulate 
phenotypic expression of hypertrophy in HCM. Recently, aldosterone has been 
implicated as a major link between sarcomeric mutations and cardiac phenotype. To 
determine whether aldosterone modulates hypertrophy in HCM, aldosterone was 
measured in left ventricular (LV) tissue of 12 organ donors and 8 patients with HCM. 
The effect of the aldosterone synthase gene (CYP11B2) C-344T polymorphism on LV 
mass index (LVMI) and interventricular septum thickness (IVS) was determined in 79 
genetically independent subjects with HCM. LVMI and IVS were measured by 2-D 
echocardiography. Extent of hypertrophy was quantified by a point score (Wigle score). 
Prorenin, renin, and ACE were determined by immunoradiometric or fluorimetric assays, 
and genotyping was performed by PCR. Aldosterone in HCM hearts equalled aldosterone 
in normal hearts hearts. In women with HCM, no associations between CYP11B2
genotype and any of the measured parameters were observed, whereas in men with HCM, 
LVMI increased with the presence of the T allele (LVMI=137±9 and 178±9 g/m2 in men 
with the CC vs. the CT+TT genotype, respectively; P=0.06). Similar T allele-related 
increases in men were observed for IVS (P=0.01) and Wigle score (P=0.08), but not for 
prorenin, renin or ACE. Multiple regression analysis revealed that the aldosterone 
synthase gene T allele-related effect on IVS occurred independently (P=0.04) of renin, 
ACE, the AT1-R gene A/C
1166 polymorphism and the AT2-R A/C
3123 polymorphism. We 
conclude that aldosterone modulates cardiac hypertrophy in men with HCM, thereby 
raising the need for studies determining the benefit of mineralocorticoid receptor 
blockade in HCM. 
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Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained 
cardiac and myocyte hypertrophy, interstitial fibrosis and myocyte disarray [1]. 
Mutations in at least 11 different sarcomeric proteins have been identified as the primary 
defect [2]. Yet, even if patients have identical causative genotypes, they still vary 
considerably by phenotype [3]. Other factors, genetic as well as environmental, may 
therefore modify the phenotypic expression of the mutated gene. Angiotensin (Ang) II, 
the end-product of the renin-angiotensin system (RAS), is among these factors. It 
modulates cardiac hypertrophy in HCM both via growth-stimulatory Ang II type 1 (AT1)
receptors and via growth-inhibitory [4] Ang II type 2 (AT2) receptors [5,6]. Its effects are 
gender-specific, and occur independently of the circulating RAS.
A recent study suggests that aldosterone, similar to Ang II, acts as a major link 
between sarcomeric mutations and cardiac phenotype in HCM [7]. According to this 
study, the myocardial aldosterone levels in humans with HCM are 4-fold elevated, and 
aldosterone provokes expression of hypertrophic markers in rat cardiac myocytes and of 
collagens in rat cardiac fibroblasts. The latter effects occurred in a mineralocorticoid 
receptor (MR)-dependent manner, as they could be blocked by the MR antagonist 
spironolactone [7,8]. Aldosterone, like Ang II [9], may be produced locally in the heart 
[10], and the aldosterone synthase (CYP11B2) polymorphism associates with left 
ventricular mass (LVM) in human essential hypertension [11]. Furthermore, MR do occur 
in the human heart [12]. 
It was the aim of the present study to further determine the role of aldosterone as a 
modulator of hypertrophy in HCM. We first measured aldosterone in cardiac tissue 
obtained during surgery of patients with HCM. Secondly, we determined the relationship 
between the aldosterone synthase (CYP11B2) polymorphism and cardiac hypertrophy in 
79 HCM patients.
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Methods
Patients
All studies were approved by the internal review board and patients gave informed 
consent. One-hundred and seventeen patients with HCM (age 21-81 years) visiting the 
HCM Clinic at the Erasmus MC between 1994 and 1997 for a routine follow-up were 
included. HCM had been diagnosed on the basis of echocardiographic criteria showing a 
nondilated, hypertrophied left ventricle (any wall thickness >15 mm) in the absence of 
known causes of left ventricular hypertrophy [13]. DNA quality and quantity allowed 
genotyping in 81 patients. Of these patients, 31 had a sporadic form of HCM and 36 had 
at least one other affected first degree family member. The family history of HCM was 
unknown in 14 patients. To avoid potential bias introduced by the presence of genetically 
dependent samples (relatives), we randomly selected one patient per family. This resulted 
in a final cohort of 79 genetically independent patients, of whom 5 were receiving an 
ACE inhibitor, 22 a -adrenergic antagonist, 39 a calcium-channel blocker and 9 a 
diuretic.
Left ventricular tissue was obtained from 8 HCM subjects (3 men, 5 women, age 
36±3 (range 16-57) years) undergoing septal myectomy [14] and from 12 heart-beating 
organ donors (5 men, 7 women, age 39±3 (range 17-54) years), who died of non-cardiac 
causes (9 cerebrovascular accident, 1 head trauma, 2 brain hypoxia) <24 hours before the 
heart was taken to the laboratory. Tissue pieces (1-10 g) were kept at -70C.
Echocardiographic Methods 
Two-dimensional echocardiography was performed with commercially available 
equipment (Toshiba Sonolayer). Images were recorded on videotape for off-line analysis 
by 2 physicians who were blinded to the genotyping results. Interventricular septal 
thickness (IVS) and LVM were determined as described before [5]. LVM was indexed 
(LVMI) to body surface area (BSA). Peak left ventricular outflow tract gradient at rest 
was estimated using the modified Bernoulli equation [5]. Since echocardiographic 
measurement of LVMI may not truly reflect the extent of hypertrophy and the 
involvement (or lack thereof) of the distal (apical) half of the septum or lateral wall, the 
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extent of hypertrophy was also assessed by a semi-quantitative point score (range 0-10) 
method developed by Wigle et al. [15].  
Biochemical Measurements 
Prorenin and renin were quantified in peripheral venous blood using an 
immunoradiometric assay kit (Nichols Institute) [16]. Prorenin and renin are expressed as 
mU/L, using the human kidney renin standard MRC 68/356 as a reference. ACE activity 
was measured with a commercial kit (ACE Color) [17]. Aldosterone was measured by 
solid-phase radioimmunoassay (DPC) following its extraction from left ventricular tissue. 
In short, tissue was homogenized 1:2 in methanol. The supernatant was collected after a 
15-min centrifugation at 3,000 rpm at 4ºC, vacuum dried, and dissolved in water. The 
detection limit was 10 pg/g wet weight, and levels below the detection limit were taken to 
be equal to the detection limit.  
Genetic Analysis 
Peripheral leukocytes were used to isolate genomic DNA in H2O using the QIAamp 
Bloodkit (QIAGEN Inc.). The aldosterone synthase gene (CYP11B2) C-344T 
polymorphism was determined according to Barbato et al.[18]. Polymerase chain reaction 
(PCR) amplifications were carried out in a 50 l reaction volume, using 10 ng of genomic 
DNA. Each reaction contained 1x PCR buffer II (Perkin Elmer), 1.5 mmol/l MgCl2, 0.2 
mmol/l each of the deoxynucleotide triphosphates (Roche), 1.25 U of Amplitaq Gold 
(Perkin Elmer) and 40 pmol each of forward primer 
5'-CAGGAGGAGACCCCATGTGAC-3' and reverse primer 
5'-CCTCCACCCTGTTCAGCCC-3'. PCR consisted of initial denaturation at 94°C for 4 
min followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 67°C for 30 
sec and extension at 72°C for 30 sec, followed by a final extension at 72°C for 5 min. For 
restriction fragment length polymorphism (RFLP) determination, the PCR product (10 
µl) was digested with Hae III for 2 hours at 37°C. The fragment sizes were analyzed on a 
4% agarose gel with ethidium bromide staining. The PCR-RFLP was validated by direct 
sequencing of PCR product from a heterozygote sample, using the Big Dye Terminator 
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Cycle Sequencing Kit (Applied Biosystems) on a ABI 310 capillary sequencer (Applied 
Biosystems). The ACE I/D polymorphism, the AT1 receptor A/C
1166 polymorphism, and 
the AT2 receptor A/C
3123 polymorphism were determined as described before [5,6].
Statistical Analysis 
Data are expressed as mean±SEM or geometric mean and range. Analysis was performed 
with the SPSS 11.0 statistical package. Hardy-Weinberg equilibrium was tested by X 2
test. Univariate and multiple regression analyses were conducted to determine the 
percentage of explained variance in LVMI and IVS that is accounted for by the genotypes 
of the candidate modifier genes and other variables. In the multiple regression analysis 
the RAS gene polymorphisms, age, peak left ventricular outflow tract gradient and renin 
concentration were tested as independent variables. Prorenin and ACE were excluded 
from this analysis because of their high correlations with renin (r=0.68, P<0.001) and 
ACE genotype (r=0.39, P=0.003), respectively. 
Results
Cardiac aldosterone levels in HCM patients (27 (10-233) pg/g, n=8) were not different 
from the aldosterone levels in hearts of organ donors (26 (10-481) pg/g, n=12).
Table 1 lists the characteristics of the HCM patients by CYP11B2 genotype. Frequencies 
of the C and T allele (0.41 and 0.59, respectively) were similar to previously reported 
numbers in normal white populations [11,18,19], and genotype frequencies were in 
agreement with Hardy-Weinberg equilibrium. The percentage of patients taking ACE 
inhibitors, -adrenergic antagonists, calcium channel blockers or diuretics did not differ 
between the various groups (data not shown). When analyzing all subjects together, no 
genotype-related differences were observed with regard to any of the measured 
parameters (Table 1), in full agreement with a previous study [20]. However, subdivision 
of the population according to gender revealed that IVS was significantly higher (P=0.01)
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Table 1 Characteristics of HCM patients according to aldosterone synthase genotype.
Parameter Genotype 
 CC (n=10) CT (n=45) TT (n=24) 
Sex, M/F 7/3 24/21 14/10 
Age, y 485 512 484
BSA, m2 1.880.05 1.810.03 1.880.04
IVS, mm 19.91.9 21.50.6 22.11.0
LVMI, g/m2 15216 1788 16910
Wigle score, 1-10 5.80.7 6.50.3 6.20.5
Gradient, mm Hg 33.68.6 54.86.0 53.08.3
Prorenin, mU/L 289119 19819 18115
Renin, mU/L 43.118.0 23.42.0 22.32.2
ACE, U/L 11.71.0 9.80.3 10.00.5
BSA, body surface area; IVS, interventricular septum thickness; LVMI, left ventricular 
mass index; gradient, peak left ventricular outflow tract gradient.
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Table 2 Characteristics of male and female HCM patients according to aldosterone 
synthase genotype. 
Parameter Genotype 
 Men Women 
 CC CT+TT CC CT+TT 
n 7 38 3 31 
Age, y 466 472 513 543
BSA, m2 1.880.05 1.810.03 1.880.04 1.880.04
IVS, mm 17.61.0 21.90.7* 25.35.8 21.50.9
LVMI, g/m2 1379 1789¶ 18353 1729
Wigle score, 1-10 5.00.8 6.40.3º 7.71.5 6.30.5
Gradient, mm Hg 33.312.3 51.06.5 34.313.2 57.87.8
Prorenin, mU/L 346167 20620 914 17316
Renin, mU/L 51.325.4 24.71.9 14.41.0 20.52.4
ACE, U/L 14.72.0 10.10.4 8.60.0 9.60.3
BSA, body surface area; IVS, interventricular septum thickness; LVMI, left ventricular 
mass index; gradient, peak left ventricular outflow tract gradient. *P=0.01, ¶P=0.06, 
ºP=0.08 vs. CC men. 
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in men carrying 1 or 2 T alleles than in male CC homozygotes. Similar trends were 
observed for LVMI (P=0.06) and Wigle score (P=0.08). No such T allele-related effects 
were observed in women, nor did any of the other parameters correlate with the presence 
of the T allele in either men or women. Univariate regression analysis showed that 
CYP11B2 genotype accounted for 16.3% of the variablity of IVS (r=0.40, P<0.01).
Multiple regression analysis revealed that this effect occurred independently (=3.71.7;
P=0.04) of renin, the ACE gene polymorphism, the AT1-R gene A/C
1166 polymorphism, 
the AT2-R A/C
3123 polymorphism, age and peak left ventricular outflow tract gradient.
Discussion
The present study shows that aldosterone, like Ang II, is among the factors that modify 
the phenotypic expression of the mutated gene in HCM. IVS was higher in male HCM 
subjects carrying the CYP11B2 T allele, and similar observations were made for LVMI 
and Wigle score. This effect occurred independently of the RAS. Contrary to our 
expectation, and opposing the recent study by Tsybouleva et al. on this subject [7], the 
left ventricular tissue levels of aldosterone in subjects with HCM were not significantly 
different from those in age-matched controls.  
Our cardiac aldosterone levels resemble the levels reported by Gomez-Sanchez et 
al. [21] and Fiebeler et al. [22] in the rat heart. These authors observed a close 
relationship between the levels of aldosterone in the heart and in blood plasma, and they 
concluded that, at least in the rat, cardiac aldosterone is largely, if not completely, of 
adrenal origin. The plasma levels of aldosterone in subjects with HCM, like those of 
renin, are in the normal range (30-200 pg/ml) [7,23,24], and thus no alteration in the 
cardiac aldosterone content of HCM subjects would be expected if cardiac aldosterone 
were exclusively of adrenal origin. Based on CYP11B2 mRNA measurements however, 
Tsybouleva et al. [7] have suggested that cardiac aldosterone is of local origin. In contrast 
with this conclusion, their cardiac aldosterone levels were <0.1 pg/g protein, i.e. >2 
orders orders of magnitude below the levels that are minimally expected based on the 
presence of blood in cardiac tissue [25,26]. Thus, conclusive evidence for cardiac 
production of aldosterone in subjects with HCM is still lacking.
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The association between CYP11B2 genotype and cardiac hypertrophy in HCM 
parallels the association between the CYP11B2 T allele and LVM in subjects with 
essential hypertension [11]. It also extends a previous study on this polymorphism in 
HCM subjects which showed no significant T allele-related increase in LVMI [20]. The 
latter study did not evaluate the gender-specificity of the effect. In addition, since the 
influence of the CYP11B2 genotype, like that of the ACE I/D genotype, will depend on 
the gene mutation that determines the primary defect [27], CYP11B2 T allele-related 
effects do not necessarily apply to all HCM populations.
According to most [11,18,19,28,29] (but not all [19,30]) studies, the CYP11B2 T
allele is associated with elevated plasma aldosterone levels, while serum aldosterone 
associates with the variability of LVM in both healthy controls and subjects with 
hypertension [31]. Thus, a picture arises in which the T allele results in elevated plasma 
levels of aldosterone, which subsequently affect cardiac hypertrophy. Indeed, there is 
ample evidence suggesting that circulating aldosterone acts as a pro-inflammatory, 
hypertrophic and profibrotic factor in the heart [7,8,32,33]. In further support of this 
concept, MR occur in the human heart [12] and 11-hydroxysteroid dehydrogenase type 
2 (11-HSD2) activity associates directly with LVM in essential hypertension [34]. 
11-HSD2 inactivates cortisol and corticosterone, thereby preventing these 
glucocorticoids from stimulating MR. The 11-HSD2 levels are relatively low in the 
heart [12], whereas the glucocorticoid concentrations in blood are several orders of 
magnitude above those of aldosterone. Thus, activation of cardiac MR by circulating 
aldosterone is possible only in the presence of sufficiently high 11-HSD2 activity. 
Importantly, the above scenario does not require the cardiac aldosterone levels to be 
elevated in HCM subjects as compared to controls, since the genotype distribution in our 
HCM population was similar to that in normal white populations [11,18,19]. 
The effect of the T allele on cardiac hypertrophy occurred independently of 
circulating renin, ACE and the two AT receptors, and thus aldosterone exerts additive 
effects on top of Ang II, despite earlier studies suggesting that aldosterone exerts its 
effects via Ang II or AT1 receptors and vice versa [35-37]. This conclusion is in full 
agreement with the renin-independent associations between LVM, CYP11B2 genotype
and 11-HSD2 activity in hypertension [11,34]. The gender-specificity of the association 
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in our study is more difficult to explain. Estrogen may mimic or antagonize some of the 
effects of aldosterone [38], whereas the well-known gender-related differences in renin 
and angiotensinogen [24,39] will affect, through Ang II, the biosynthesis of aldosterone.     
Finally, the MR antagonist spironolactone has been demonstrated to reduce the 
extent of myocyte disarray and to reverse interstitial fibrosis in a transgenic mouse model 
of human HCM mutation (cTnT-Q92 mice) [7]. Interestingly, these mice did not display 
elevated cardiac aldosterone levels [7]. Combined with the results from the present study, 
these data raise the need for studies determining the benefit of MR blockade in HCM. 
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Summary
Introduction and aim (Chapter 1) 
Classically, aldosterone is an adrenal-derived steroid that acts through intracellular 
mineralocorticoid receptors (MR) in the kidney. Angiotensin (Ang) II, synthesized 
locally in the adrenal or derived from the circulation, is among the factors that stimulate 
aldosterone synthesis. Two recent clinical trials with MR antagonists have shown 
beneficial effects of these drugs on top of renin-angiotensin system blockade, which 
cannot be attributed solely to blockade of the renal MR-mediated effects on blood 
pressure. Therefore, it is now generally assumed that aldosterone also exerts actions 
outside the kidney.
This chapter summarizes the recent findings in this area, focusing also on the idea 
that aldosterone exerts extrarenal actions through a novel (so far unidentified) membrane 
receptor. A distinction is made between the classic ‘genomic’ (occurring after hours and 
involving DNA-directed, RNA-mediated protein synthesis) and the novel ‘non-genomic’ 
(occurring with minutes and not involving DNA-directed, RNA-mediated protein 
synthesis) effects of aldosterone. Another controversial issue is whether aldosterone 
synthesis also occurs outside the adrenal, e.g. in the heart. Aldosterone synthase 
expression has been demonstrated in various non-adrenal cells.
It was the aim of the present study to unravel first to what degree locally or 
blood-derived Ang II contributes to adrenal aldosterone synthesis, and whether this local 
production of Ang II, if occurring, takes place intra- or extracellularly. Second, we 
studied the genomic and non-genomic effects of aldosterone in the rat heart, under 
normal and ischemic conditions, and we verified the source of cardiac aldosterone. Third, 
we investigated the effects of aldosterone in human myocardial trabeculae and coronary 
arteries and the second messengers mediating these effects. We also compared the cardiac 
levels of aldosterone in healthy and diseased human hearts, and we investigated the 
association of the aldosterone synthase gene (CYP11B2) C-344T polymorphism with 
cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. 
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Origin and site of synthesis of Ang II in the adrenal (Chapters 2 and 3) 
Infusions of 125I-radiolabeled angiotensins in pigs revealed that circulating 125I-Ang II, 
but not circulating 125I-Ang I, accumulates in the adrenal, reaching steady-state levels that 
are 15-20 times higher than its levels in blood plasma. Yet, the levels of endogenous Ang 
II are almost 400 times higher than the Ang II levels in blood, and, thus, the majority of 
adrenal Ang II is synthesized locally from locally generated Ang I. The Ang II type 1 
(AT1) receptor antagonist eprosartan greatly reduced the adrenal uptake of circulating 
125I-Ang II, and increased plasma Ang II to a greater degree than tissue Ang II. As a 
consequence, eprosartan equally reduced the tissue/plasma concentration ratios of both 
Ang II and 125I-Ang II.
 From these data it can be concluded that adrenal Ang II generation occurs 
extracellularly, and is followed by internalization via AT1 receptor-mediated endocytosis. 
Apparently therefore, the truncated prorenin (with full enzymatic activity) that occurs 
intracellularly in adrenal tissue, exerts functions other than generating Ang I, in 
agreement with the fact that angiotensinogen-synthesizing cells release angiotensinogen 
into the extracellular space rather storing it intracellularly.   
Effects of aldosterone in the rat heart (Chapters 4 and 5) 
In the isolated perfused rat Langendorff heart, aldosterone, like Ang II, rapidly increased 
left ventricular pressure and decreased coronary flow. The MR antagonists spironolactone 
and eplerenone did not block these effects. In fact, spironolactone exerted similar 
inotropic effects on top of aldosterone, and thus it appears that the effects of aldosterone 
on inotropy and flow occur in a ‘non-genomic’ (non-MR-mediated) manner.  
 Both spironolactone and eplerenone greatly improved the condition of the heart 
following ischemia and reperfusion (infarct size , left ventricular pressure recovery ,
arrhythmia incidence ), suggesting that these drugs interfere with the deleterious effects 
of endogenous aldosterone. Perfusion studies with aldosterone showed that the steroid 
rapidly accumulated in cardiac tissue, not only in extracellular (interstitial) fluid, but also 
in a second, as yet unidentified, compartment. Washout from this second compartment 
occurred relatively rapid (half life < 10 minutes), and after prolonged washout the cardiac 
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aldosterone levels were close to or below the detection limit. Thus, the majority of 
cardiac aldosterone is blood-derived. 
 In cultured aortic smooth muscle cells, low concentrations of aldosterone 
enhanced the effect of Ang II on DNA synthesis. Higher aldosterone concentrations 
reduced DNA synthesis, both in smooth muscle cells and in cardiac myocytes. High 
aldosterone concentrations also reduced collagen synthesis in cardiac fibroblasts. 
Spironolactone blocked the effects on both DNA and collagen synthesis, suggesting that 
they are MR-mediated and of ‘genomic’ nature.  
In conclusion, aldosterone induces positive inotropic and vasoconstrictor effects 
in the rat heart in a non-genomic manner, and these effects are comparable to those of 
Ang II. MR stimulation reduces DNA and collagen synthesis in cardiac cells, and 
worsens the condition of the heart post-coronary artery occlusion. Interference with the 
latter phenomena may underlie, at least in part, the beneficial actions of MR antagonists 
in heart failure. 
Effects of aldosterone in the human heart (Chapters 6 and 7) 
In human myocardial trabeculae, aldosterone induced a negative inotropic response, in 
apparent contrast with its positive inotropic effects in the rat heart. The protein kinase C 
(PKC) inhibitor chelerythrine chloride, but not the MR antagonists spironolactone or 
eplerenone, blocked this negative inotropic effect, suggesting that it is mediated via a 
non-MR in a PKC-dependent manner. The aldosterone concentrations required to induce 
this effect were in the high nanomolar range, i.e. a range that occurred in failing hearts 
only.
The cardiac aldosterone levels correlated with the cardiac levels of renin (which is 
exclusively of renal origin). Possibly therefore, cardiac aldosterone, like cardiac renin, is 
of extracardiac origin. In support of this concept, the cardiac and plasma concentrations 
of aldosterone in subjects with hypertrophic cardiomyopathy were identical to those in 
normal subjects, despite the fact that the aldosterone synthase gene (CYP11B2) C-344T 
polymorphism associated with cardiac hypertrophy in these subjects. The most likely 
explanation of this finding is that the T allele-related increases in plasma aldosterone are 
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the underlying cause of the relationship between the T allele and cardiac hypertrophy, 
presumably because they lead to increased cardiac aldosterone levels.  
 In human coronary arteries, aldosterone exerted no constrictor or dilator effect by 
itself. However, prior exposure to 1 mol/L aldosterone greatly enhanced the constrictor 
response to Ang II. At the second messenger level, this was reflected by an increase in 
the level of phosphorylated ERK 1/2. Hydrocortisone and 17-estradiol induced similar 
potentiating effects, but only in the case of aldosterone these effects occurred at the 
subnanomolar level, i.e., in a physiological range.
In summary, aldosterone induces a negative inotropic response in human 
trabeculae (thereby antagonizing the well-known positive inotropic actions of Ang II) and 
potentiates the vasoconstrictor effect of Ang II in coronary arteries. These effects occur in 
a non-genomic manner and involve PKC and ERK 1/2, respectively.
General Discussion and Future Studies 
Truncated prorenin
Although virtually all adrenal Ang II is located intracellularly, our data do not support the 
concept of intracellular angiotensin generation. Thus, it remains unclear why truncated 
prorenin is transported into mitochondria (the site of aldosterone biosynthesis) in the 
adrenal [1]. Truncated prorenin has been demonstrated elsewhere in the body [2], and it is 
not known to what degree it occurs in circulating blood. Interestingly, truncated prorenin 
is enzymatically active, because it has a prosegment of insufficient length, which does  
not allow full coverage of the enzymatic cleft. Future studies should now investigate 
whether truncated prorenin is released into the extracellular space, and, if so, whether this 
‘prorenin’ contributes to extracellular angiotensin generation. This concept is even more 
important now that a (pro)renin receptor has been discovered [3]. This receptor allows 
prorenin to display full enzymatic activity once it is bound to the receptor. Antibodies 
directed against various regions of the prosegment are required to address this issue [4].
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Cardiac inotropy 
Although aldosterone exerts opposite inotropic effects in the human and rat heart, a 
common second messenger pathway (the PKC – inositol 1,4,5-trisphosphate (IP3)-1,2
diacylglycerol (DAG) pathway) may underlie both phenomena. This pathway leads to an 
increase in intracellular Ca2+ and stimulation of the Na+/H+ exchanger [5-10]. The latter 
stimulation causes a rise in intracellular Na+. This subsequently activates Na+/K+-
ATPase, thereby inducing a negative inotropic effect. During blockade of the rise in 
intracellular Na+ however, aldosterone decreases Na+/K+-ATPase activity in a PKC-
dependent manner [9], thus inducing a positive inotropic effect. Future studies, making 
use of inhibitors of the rise in intracellular Na+ and/or Na+/K+-ATPase, should now 
address this issue in further detail. Such studies should also evaluate the PKC subtype and 
the interaction (synergy or antagonism) with Ang II, in particular because Ang II appears 
to activate the same intracellular signaling pathway [11].  
Furthermore, although both spironolactone and eplerenone did not block the 
inotropic effects of aldosterone, it has been reported that a closed ring MR antagonist 
such as spironolactone is ineffective in acute in vitro experiments, whereas an open ring, 
water-soluble MR antagonist is effective under such conditions [5]. Thus, more work 
with other MR antagonists is needed to fully exclude a role for the MR in the inotropic 
response of aldosterone.
Coronary vasoconstriction; interaction with angiotensin II 
The aldosterone-induced potentiation of Ang II, both in human coronary arteries and rat 
vascular smooth muscle cells, needs to be explored in further detail, in vitro as well as in 
vivo. Our studies in porcine renal arteries have already demonstrated that the potentiating 
effects of aldosterone occur at picomolar concentrations. Future investigations should 
now address to what degree this potentiation concerns aldosterone-induced endothelial 
dysfunction [12,13], and/or an interaction at the level of smooth muscle cells, involving 
some or all of the mediators that have recently been coupled to aldosterone, e.g., the PKC 
– IP3 – DAG pathway, Na
+/H+ exchange, Na+/K+-ATPase, p38 MAP kinase, reactive 
oxygen species and/or the epidermal growth factor receptor [7,14,15]. More work with 
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other MR antagonists is needed to fully exclude a role for the MR in this potentiation, as 
described above. Venous occlusion plethysmography studies using the forearm might 
substantiate the Ang II-aldosterone interaction in vivo, e.g., during treatment with MR 
antagonists and/or AT1 receptor antagonists. Finally, the possibility of aldosterone-
induced, NO-mediated vasodilation, proposed by several investigators [7,16], needs to be 
addressed more extensively, preferably making use of vessels that display excellent 
endothelial function [17]. 
 
Clinical relevance 
The protective effect of MR antagonism in the Langendorff heart during ischemia and 
reperfusion most likely relates to the suppression of arrhythmias, in full agreement with 
the recent observation that conditional MR overexpression in the mouse heart results in 
life-threatening arrhythmias [18]. It cannot be explained on the basis of the 
vasoconstrictor effect of aldosterone, as proposed by Fujita et al. [19], unless our inability 
to block aldosterone-induced vasoconstriction in vitro with either spironolactone or 
eplerenone does not apply in vivo. A suppression of arrhythmias through MR antagonism 
would offer an explanation for the reduction in sudden death in RALES and EPHESUS 
[20,21].  
In view of the comparable outcome of RALES and EPHESUS, future studies 
should also critically evaluate the physiological importance of the inotropic effects of 
spironolactone. If indeed the non-genomic effects of aldosterone on inotropy and 
vasoconstriction are mediated through a non-MR, aldosterone synthase inhibitors might 
yield effects on top of MR blockade. Obviously, the identity of the non-MR, if existing, 
should be established as soon as possible. 
 Finally, the association between the aldosterone synthase (CYP11B2) T allele and 
cardiac hypertrophy in subjects with hypertrophic cardiomyopathy raises the need for 
studies determining the benefit of MR blockade in this disease. In favor of this concept, 
MR blockade diminishes oxidative stress, inflammation and fibrosis, although it is not yet 
clear whether this relates to direct effects in the heart (mediated via fibroblasts) and/or 
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indirect peripheral effects (mediated via oxidative stress-activated mononuclear cells) 
[22]. 
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Nederlandse Samenvatting 
Introductie en doelstelling (Hoofdstuk 1) 
Van oudsher wordt aldosteron gezien als een steroïd uit de bijnier dat in de nieren werkt 
door activatie van intracellulaire mineralocorticoïde receptoren (MR). Angiotensine 
(Ang) II, hetzij lokaal in de bijnier gevormd of aangevoerd via de bloedbaan, is één van 
de factoren die de aldosteron synthese stimuleert. Twee recente klinische studies hebben 
gunstige effecten van MR antagonisten aangetoond bij patiënten met hartfalen, en dit kon 
niet alleen worden verklaard door blokkade van de renale MR-gemediëerde effecten op 
de bloeddruk. Er wordt nu verondersteld dat aldosteron ook effecten heeft buiten de 
nieren.
Dit hoofdstuk geeft een overzicht van de recente bevindingen op dit terrein en 
beschrijft ook de hypothese dat aldosteron extrarenale effecten heeft via een nieuwe (tot 
dusver niet-geïdentificeerde) membraan-gebonden receptor. Een onderscheid wordt 
gemaakt tussen de klassieke ‘genomische’ (bewerkstelligd na uren, en afhankelijk van de
novo eiwitsynthese) en de nieuwe ‘niet-genomische’ (bewerkstelligd binnen minuten, 
zonder de novo eiwitsynthese) effecten van aldosteron. Een controversieel vraagstuk is 
tevens of aldosteron synthese ook buiten de bijnier geschiedt, bijvoorbeeld in het hart. 
Expressie van het belangrijke enzym aldosteron synthase is bijvoorbeeld aangetoond in 
verschillende cellen buiten de bijnier, inclusief die van het hart.  
De doelstelling van de huidige studie is ten eerste te ontrafelen in hoeverre lokaal 
of uit bloed afkomstig Ang II de aldosteron synthese in de bijnier stimuleert, en tevens 
vast te stellen of de lokale produktie van Ang II in de bijnier intra- of extracellulair 
plaatsvindt. De genomische en niet-genomische effecten van aldosteron werden 
vervolgens bestudeerd in het hart van de rat, zowel onder normale als ischemische 
condities, en ook werd de bron van cardiaal aldosteron onderzocht. Tevens werden de 
effecten van aldosteron in humane myocardiale trabekels en coronaire arteriën 
gekwantificeerd, evenals de betrokken second messengers. Tenslotte werd aldosteron 
gemeten in normale en falende humane harten, en is bekeken of er een associatie is tussen 
het aldosteron synthase gen (CYP11B2) C-344T polymorfisme en de mate van cardiale 
hypertrofie bij patiënten met hypertrofe cardiomyopathie. 
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Oorsprong en plaats van vorming van Ang II in de bijnier (Hoofdstukken 2 en 3) 
Infusie van [125I]-gelabelde angiotensines bij varkens liet zien dat circulerend [125I]-Ang 
II, maar niet circulerend [125I]-Ang I, zich ophoopt in de bijnier. Tijdens steady-state is de 
[125I]-Ang II spiegel in de bijnier 15-20 keer hoger dan in bloed. Echter, omdat de 
hoeveelheid endogeen Ang II in de bijnier ongeveer 400 keer hoger is dan die in bloed, 
wordt het overgrote deel van bijnier-Ang II toch lokaal in de bijnier gesynthetiseerd, 
vanuit lokaal gevormd Ang I. De Ang II type 1 (AT1) receptor antagonist eprosartan 
reduceerde de 125I-Ang II ophoping in de bijnier fors, en deed de Ang II concentratie in 
bloed sterker stijgen dan die in de bijnier. Als gevolg hiervan reduceerde eprosartan de 
weefsel/plasma Ang II concentratie ratio even sterk voor endogeen Ang II als voor 125I-
Ang II.
 Hieruit kan worden geconcludeerd dat de vorming van Ang II in de bijnier 
extracellulair geschiedt, en wordt gevolgd door internalisatie via AT1 receptor-
gemediëerde endocytose. Kennelijk heeft het getrunceerde prorenine dat intracellulair 
voorkomt in bijnierweefsel (en dat volledig enzymatisch actief is), een andere functie dan 
Ang I vorming. Deze conclusie klopt ook met het feit dat cellen die angiotensinogeen 
maken dit meteen uitscheiden zonder het intracellulair op te slaan.
Effecten van aldosteron in het rattehart (Hoofdstukken 4 en 5) 
In het geïsoleerde rattehart, geperfuseerd volgens Langendorff, verhoogde aldosteron de 
linker ventrikel druk en verlaagde het de coronairflow. Deze effecten zijn vergelijkbaar 
met die van Ang II. De MR antagonisten spironolacton and eplerenon blokkeerden de 
effecten van aldosteron niet. Spironolacton veroorzaakte zelfs vergelijkbare inotrope 
effecten, en het lijkt er dus op dat de effecten van aldosteron op flow en inotropie niet-
genomisch van aard zijn.  
 Zowel spironolacton als eplerenon verbeterden de hartconditie na ischemie en 
reperfusie (infarctgrootte , herstel linker ventrikel druk , optreden van aritmieën ),
hetgeen suggereert dat deze stoffen met de schadelijke effecten van endogeen aldosteron 
interfereren. Perfusiestudies met aldosteron lieten zien dat het steroïd zich snel ophoopt in 
het hart, zowel in de extracellulaire (interstitiële) ruimte als in een tweede, nog niet-
                                                                                                                                Summary
97
geïdentificeerd compartiment. Het uitwassen vanuit dit tweede compartiment gebeurde 
relatief snel (halfwaardetijd < 10 minuten), en na langdurig wassen lagen de aldosteron 
concentraties in het hart rond de detectielimiet. Dit betekent dat het grootste deel van het 
cardiale aldosteron uit bloed afkomstig is.  
 In gladde spiercellen uit de aorta bleken lage aldosteron concentraties het effect 
van Ang II op DNA synthese te versterken. Hogere aldosteron concentraties verlaagden 
juist de DNA synthese, zowel in gladde spiercellen als in cardiomyocyten. Hoge 
aldosteron concentraties reduceerden ook de collageen synthese in cardiofibroblasten. 
Spironolacton blokkeerde deze effecten van aldosteron, hetgeen suggereert dat de 
effecten op de synthese van DNA en collageen gemediëerd worden door MR en dus 
genomisch van aard zijn. 
Samenvattend kan gesteld worden dat aldosteron positief inotrope en 
vasoconstrictoire effecten induceert in het rattehart via een niet-genomisch mechanisme, 
en dat deze effecten vergelijkbaar zijn met die van Ang II. MR stimulatie verlaagt de 
DNA en collageen synthese in hartcellen en verslechtert de conditie van het hart na het 
afsluiten van coronaire arteriën. Blokkade van deze laatste fenomenen zou ten grondslag 
kunnen liggen aan (een deel van) de gunstige effecten van MR antagonisten bij hartfalen. 
Effecten van aldosteron in het humane hart (Hoofdstukken 6 en 7) 
Aldosteron induceerde een negatief inotroop effect in humane myocardiale trabekels, in 
tegenstelling tot de positief inotrope effecten die eerder werden gezien in het rattehart. De 
proteïne kinase C (PKC) remmer chelerythrine chloride, maar niet de MR antagonisten 
spironolacton en eplerenon, blokkeerde het negatief inotrope effect. Kennelijk wordt het 
dus gemedieerd via een PKC-afhankelijk, MR-onafhankelijk mechanisme. De aldosteron 
concentraties die nodig waren om het negatief inotrope effect te induceren waren hoog en 
kwamen alleen voor in falende harten.  
De aldosteron concentraties in het hart correleerden met die van renine, terwijl 
bekend is dat cardiaal renine uit de nieren afkomstig is. Het is daarom niet 
onwaarschijnlijk dat ook cardiaal aldosteron haar oorsprong heeft buiten het hart. 
Ondersteuning van dit concept wordt verkregen uit onze bevinding dat de cardiale en 
plasma concentraties van aldosteron bij patiënten met hypertrofe cardiomyopathie 
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identiek waren aan die van gezonde personen, ondanks het feit dat het aldosteron 
synthase gen (CYP11B2) C-344T polymorfisme geassocieerd is met de mate van cardiale 
hypertrofie bij deze patiënten. De meest voor de hand liggende verklaring van deze 
bevinding is dat de T allel-gerelateerde toename in plasma aldosteron de onderliggende 
reden is voor de relatie tussen het T-allel en cardiale hypertrofie, waarschijnlijk omdat 
deze leidt tot een parallelle verhoging van de cardiale aldosteron concentraties.  
 Aldosteron zelf had geen effect in humane coronaire arteriën. Voorafgaande 
blootstelling aan aldosteron verdubbelde echter de constrictoire respons op Ang II, 
waarschijnlijk door inductie van ERK1/2 fosforylering. Hydrocortison en 17-estradiol
potentieerden Ang II eveneens, maar daarvoor waren veel hogere (niet-fysiologische) 
concentraties nodig.
Concluderend induceert aldosteron een negatief inotroop effect in humane 
trabekels (daarmee het bekende positief inotrope effect van Ang II tegengaand) en 
potentieert het de vasoconstrictoire effecten van Ang II in coronaire arteriën. Deze 
effecten zijn non-genomisch van aard, en verlopen respectievelijk via PKC en ERK 1/2. 
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
--
/

---
(ACEI)II(AT1)

(RALESEP
HESUS)


--
II


-
-



()



II

()/
(125I)III
II/I90%II
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II



(nongenomi-effects)

(genomic-effects)
-


IIDNA
II


10

Eplerenone


()II

II
II
ERK1/2
non-genomic



                                                                                                                                Summary
101
()
C-344T
C-344T


--

II



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